WO2019197549A1 - Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase - Google Patents
Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase Download PDFInfo
- Publication number
- WO2019197549A1 WO2019197549A1 PCT/EP2019/059302 EP2019059302W WO2019197549A1 WO 2019197549 A1 WO2019197549 A1 WO 2019197549A1 EP 2019059302 W EP2019059302 W EP 2019059302W WO 2019197549 A1 WO2019197549 A1 WO 2019197549A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- absent
- phenyl
- substituted
- compound
- alkyl
- Prior art date
Links
- 102000003903 Cyclin-dependent kinases Human genes 0.000 title claims description 30
- 108090000266 Cyclin-dependent kinases Proteins 0.000 title claims description 30
- RXQZLSRIOOYKLF-UHFFFAOYSA-N 5H-pyrazolo[4,3-d]triazine Chemical compound N1=NN=C2C=NNC2=C1 RXQZLSRIOOYKLF-UHFFFAOYSA-N 0.000 title description 4
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title description 3
- 229940124639 Selective inhibitor Drugs 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 69
- 201000010099 disease Diseases 0.000 claims abstract description 55
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 11
- 208000026278 immune system disease Diseases 0.000 claims abstract description 11
- 230000002062 proliferating effect Effects 0.000 claims abstract description 11
- 239000013543 active substance Substances 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 482
- 239000000203 mixture Substances 0.000 claims description 316
- 238000000034 method Methods 0.000 claims description 231
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 195
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 180
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 180
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 102
- 125000000623 heterocyclic group Chemical group 0.000 claims description 85
- 229910052736 halogen Inorganic materials 0.000 claims description 73
- 150000002367 halogens Chemical class 0.000 claims description 73
- 101710106276 Cyclin-dependent kinase 7 Proteins 0.000 claims description 59
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 claims description 59
- 229910052739 hydrogen Inorganic materials 0.000 claims description 52
- 239000001257 hydrogen Substances 0.000 claims description 52
- 206010028980 Neoplasm Diseases 0.000 claims description 43
- 125000001072 heteroaryl group Chemical group 0.000 claims description 43
- 150000002431 hydrogen Chemical class 0.000 claims description 40
- -1 - OR5 Inorganic materials 0.000 claims description 35
- 229910052757 nitrogen Inorganic materials 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 125000001188 haloalkyl group Chemical group 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 30
- 208000015181 infectious disease Diseases 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 206010014599 encephalitis Diseases 0.000 claims description 24
- 108091007914 CDKs Proteins 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 21
- 201000006417 multiple sclerosis Diseases 0.000 claims description 21
- 206010047115 Vasculitis Diseases 0.000 claims description 16
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 15
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 14
- 210000003169 central nervous system Anatomy 0.000 claims description 14
- 201000002491 encephalomyelitis Diseases 0.000 claims description 14
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 11
- 201000009030 Carcinoma Diseases 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 201000008197 Laryngitis Diseases 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 230000002103 transcriptional effect Effects 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 208000000655 Distemper Diseases 0.000 claims description 8
- 201000009906 Meningitis Diseases 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 8
- 206010039491 Sarcoma Diseases 0.000 claims description 8
- 206010046851 Uveitis Diseases 0.000 claims description 8
- 230000001154 acute effect Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 201000011475 meningoencephalitis Diseases 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 241000282472 Canis lupus familiaris Species 0.000 claims description 6
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 206010015218 Erythema multiforme Diseases 0.000 claims description 6
- 208000007514 Herpes zoster Diseases 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010024229 Leprosy Diseases 0.000 claims description 6
- 102000029797 Prion Human genes 0.000 claims description 6
- 108091000054 Prion Proteins 0.000 claims description 6
- 208000025747 Rheumatic disease Diseases 0.000 claims description 6
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 6
- 230000001594 aberrant effect Effects 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 201000008275 breast carcinoma Diseases 0.000 claims description 6
- 208000014058 canine distemper Diseases 0.000 claims description 6
- 230000025084 cell cycle arrest Effects 0.000 claims description 6
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 6
- 206010028417 myasthenia gravis Diseases 0.000 claims description 6
- 230000006654 negative regulation of apoptotic process Effects 0.000 claims description 6
- 230000002018 overexpression Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 201000004409 schistosomiasis Diseases 0.000 claims description 6
- 210000003491 skin Anatomy 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 208000004881 Amebiasis Diseases 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010006500 Brucellosis Diseases 0.000 claims description 4
- 241000222122 Candida albicans Species 0.000 claims description 4
- 206010007134 Candida infections Diseases 0.000 claims description 4
- 241000282465 Canis Species 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 206010059547 Cutaneous larva migrans Diseases 0.000 claims description 4
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims description 4
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims description 4
- 208000030820 Ebola disease Diseases 0.000 claims description 4
- 241000282324 Felis Species 0.000 claims description 4
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 4
- 206010019659 Hepatic echinococciasis Diseases 0.000 claims description 4
- 206010061598 Immunodeficiency Diseases 0.000 claims description 4
- 208000009388 Job Syndrome Diseases 0.000 claims description 4
- 208000004204 Larva Migrans Diseases 0.000 claims description 4
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 4
- 208000004554 Leishmaniasis Diseases 0.000 claims description 4
- 208000031888 Mycoses Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 241000243985 Onchocerca volvulus Species 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 4
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 claims description 4
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 claims description 4
- 208000000474 Poliomyelitis Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 4
- 201000000582 Retinoblastoma Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 4
- 208000000491 Tendinopathy Diseases 0.000 claims description 4
- 206010043255 Tendonitis Diseases 0.000 claims description 4
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims description 4
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 206010046431 Urethral cancer Diseases 0.000 claims description 4
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 4
- 208000024780 Urticaria Diseases 0.000 claims description 4
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims description 4
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
- 206010047505 Visceral leishmaniasis Diseases 0.000 claims description 4
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims description 4
- 208000000260 Warts Diseases 0.000 claims description 4
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 201000003894 alveolar echinococcosis Diseases 0.000 claims description 4
- 208000003455 anaphylaxis Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims description 4
- 201000003984 candidiasis Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000016532 chronic granulomatous disease Diseases 0.000 claims description 4
- 201000010549 croup Diseases 0.000 claims description 4
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 210000000959 ear middle Anatomy 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 201000010175 gallbladder cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 206010051040 hyper-IgE syndrome Diseases 0.000 claims description 4
- 208000036260 idiopathic disease Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 210000000867 larynx Anatomy 0.000 claims description 4
- 208000028454 lice infestation Diseases 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 201000005962 mycosis fungoides Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 claims description 4
- 208000002042 onchocerciasis Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000000317 pneumocystosis Diseases 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000000306 sarcoidosis Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 201000010153 skin papilloma Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000006379 syphilis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 201000004415 tendinitis Diseases 0.000 claims description 4
- 230000000472 traumatic effect Effects 0.000 claims description 4
- 201000008827 tuberculosis Diseases 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 claims description 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 2
- 206010061618 Acanthamoeba infection Diseases 0.000 claims description 2
- 208000020222 Acanthamoeba infectious disease Diseases 0.000 claims description 2
- 206010063409 Acarodermatitis Diseases 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 claims description 2
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 208000000230 African Trypanosomiasis Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 206010001935 American trypanosomiasis Diseases 0.000 claims description 2
- 206010001980 Amoebiasis Diseases 0.000 claims description 2
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 208000028185 Angioedema Diseases 0.000 claims description 2
- 201000003076 Angiosarcoma Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000008715 Ascaridida Infections Diseases 0.000 claims description 2
- 201000002909 Aspergillosis Diseases 0.000 claims description 2
- 208000036641 Aspergillus infections Diseases 0.000 claims description 2
- 206010060971 Astrocytoma malignant Diseases 0.000 claims description 2
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims description 2
- 241000972773 Aulopiformes Species 0.000 claims description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 claims description 2
- 241000193738 Bacillus anthracis Species 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000005740 Blastocystis Infections Diseases 0.000 claims description 2
- 206010005098 Blastomycosis Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003508 Botulism Diseases 0.000 claims description 2
- 206010006143 Brain stem glioma Diseases 0.000 claims description 2
- 206010006417 Bronchial carcinoma Diseases 0.000 claims description 2
- 206010069747 Burkholderia mallei infection Diseases 0.000 claims description 2
- 206010006811 Bursitis Diseases 0.000 claims description 2
- 241000680578 Canid alphaherpesvirus 1 Species 0.000 claims description 2
- 206010007187 Capillariasis Diseases 0.000 claims description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000026368 Cestode infections Diseases 0.000 claims description 2
- 208000024699 Chagas disease Diseases 0.000 claims description 2
- 201000006082 Chickenpox Diseases 0.000 claims description 2
- 206010061041 Chlamydial infection Diseases 0.000 claims description 2
- 208000035086 Chlamydophila Infections Diseases 0.000 claims description 2
- 206010008631 Cholera Diseases 0.000 claims description 2
- 206010008642 Cholesteatoma Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009344 Clonorchiasis Diseases 0.000 claims description 2
- 241000223205 Coccidioides immitis Species 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 241001429382 Coxsackievirus A16 Species 0.000 claims description 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 2
- 206010011409 Cross infection Diseases 0.000 claims description 2
- 208000008953 Cryptosporidiosis Diseases 0.000 claims description 2
- 206010011502 Cryptosporidiosis infection Diseases 0.000 claims description 2
- 206010061802 Cyclosporidium infection Diseases 0.000 claims description 2
- 201000003808 Cystic echinococcosis Diseases 0.000 claims description 2
- 201000000077 Cysticercosis Diseases 0.000 claims description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 2
- 208000001490 Dengue Diseases 0.000 claims description 2
- 206010012310 Dengue fever Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 206010059352 Desmoid tumour Diseases 0.000 claims description 2
- 208000000398 DiGeorge Syndrome Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 2
- 241000935792 Dipylidium caninum Species 0.000 claims description 2
- 208000010772 Dog disease Diseases 0.000 claims description 2
- 206010013700 Drug hypersensitivity Diseases 0.000 claims description 2
- 206010013952 Dysphonia Diseases 0.000 claims description 2
- 206010014096 Echinococciasis Diseases 0.000 claims description 2
- 208000009366 Echinococcosis Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000966 Enoplida Infections Diseases 0.000 claims description 2
- 241000146407 Entamoeba coli Species 0.000 claims description 2
- 241000204733 Entamoeba dispar Species 0.000 claims description 2
- 241000146401 Entamoeba hartmanni Species 0.000 claims description 2
- 241000146402 Entamoeba polecki Species 0.000 claims description 2
- 206010014909 Enterovirus infection Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims description 2
- 206010061126 Escherichia infection Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 208000004413 Eyelid Neoplasms Diseases 0.000 claims description 2
- 206010050497 Eyelid tumour Diseases 0.000 claims description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 claims description 2
- 241000714165 Feline leukemia virus Species 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 2
- 208000024160 Fuchs heterochromic iridocyclitis Diseases 0.000 claims description 2
- 206010017543 Fungal skin infection Diseases 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 208000021309 Germ cell tumor Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 201000003641 Glanders Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010018612 Gonorrhoea Diseases 0.000 claims description 2
- 206010018691 Granuloma Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 208000037357 HIV infectious disease Diseases 0.000 claims description 2
- 206010061192 Haemorrhagic fever Diseases 0.000 claims description 2
- 206010019143 Hantavirus pulmonary infection Diseases 0.000 claims description 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 206010019375 Helicobacter infections Diseases 0.000 claims description 2
- 208000006050 Hemangiopericytoma Diseases 0.000 claims description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 208000032843 Hemorrhage Diseases 0.000 claims description 2
- 208000025164 Hendra virus infection Diseases 0.000 claims description 2
- 208000000464 Henipavirus Infections Diseases 0.000 claims description 2
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 208000002291 Histiocytic Sarcoma Diseases 0.000 claims description 2
- 201000002563 Histoplasmosis Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010020429 Human ehrlichiosis Diseases 0.000 claims description 2
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims description 2
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims description 2
- 206010062767 Hypophysitis Diseases 0.000 claims description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 2
- 208000004467 Infectious Canine Hepatitis Diseases 0.000 claims description 2
- 206010061217 Infestation Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims description 2
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 claims description 2
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 2
- 206010023076 Isosporiasis Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 208000011200 Kawasaki disease Diseases 0.000 claims description 2
- 241000713102 La Crosse virus Species 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010023880 Laryngitis viral Diseases 0.000 claims description 2
- 206010023927 Lassa fever Diseases 0.000 claims description 2
- 206010024238 Leptospirosis Diseases 0.000 claims description 2
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000016604 Lyme disease Diseases 0.000 claims description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 208000000932 Marburg Virus Disease Diseases 0.000 claims description 2
- 201000011013 Marburg hemorrhagic fever Diseases 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 206010027202 Meningitis bacterial Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010059282 Metastases to central nervous system Diseases 0.000 claims description 2
- 206010027457 Metastases to liver Diseases 0.000 claims description 2
- 206010027761 Mixed hepatocellular cholangiocarcinoma Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000010164 Multifocal Choroiditis Diseases 0.000 claims description 2
- 206010049816 Muscle tightness Diseases 0.000 claims description 2
- 241000513886 Mycobacterium avium complex (MAC) Species 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 206010061302 Myringitis Diseases 0.000 claims description 2
- 208000033212 Myringitis bullous Diseases 0.000 claims description 2
- 206010056970 Naegleria infection Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 241000244206 Nematoda Species 0.000 claims description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000007316 Neurocysticercosis Diseases 0.000 claims description 2
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000010505 Nose Neoplasms Diseases 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010033079 Otitis media acute Diseases 0.000 claims description 2
- 206010033081 Otitis media chronic Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 2
- 208000004788 Pars Planitis Diseases 0.000 claims description 2
- 208000008071 Parvoviridae Infections Diseases 0.000 claims description 2
- 206010057343 Parvovirus infection Diseases 0.000 claims description 2
- 241000517307 Pediculus humanus Species 0.000 claims description 2
- 201000011152 Pemphigus Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 201000005702 Pertussis Diseases 0.000 claims description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 2
- 208000007641 Pinealoma Diseases 0.000 claims description 2
- 206010035148 Plague Diseases 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 claims description 2
- 208000005374 Poisoning Diseases 0.000 claims description 2
- 206010036011 Polioencephalitis Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 208000001676 Polyomavirus Infections Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 208000031951 Primary immunodeficiency Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 241000125945 Protoparvovirus Species 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010037688 Q fever Diseases 0.000 claims description 2
- 206010037742 Rabies Diseases 0.000 claims description 2
- 208000019155 Radiation injury Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000035415 Reinfection Diseases 0.000 claims description 2
- 208000033464 Reiter syndrome Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 241000606651 Rickettsiales Species 0.000 claims description 2
- 208000000705 Rift Valley Fever Diseases 0.000 claims description 2
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 claims description 2
- 206010067470 Rotavirus infection Diseases 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010039438 Salmonella Infections Diseases 0.000 claims description 2
- 208000006775 Sarcocystosis Diseases 0.000 claims description 2
- 241000447727 Scabies Species 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 208000014286 Serpiginous choroiditis Diseases 0.000 claims description 2
- 206010040550 Shigella infections Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 206010041736 Sporotrichosis Diseases 0.000 claims description 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 2
- 206010061372 Streptococcal infection Diseases 0.000 claims description 2
- 208000004732 Systemic Vasculitis Diseases 0.000 claims description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 206010043376 Tetanus Diseases 0.000 claims description 2
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims description 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 2
- 206010044269 Toxocariasis Diseases 0.000 claims description 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 2
- 206010044608 Trichiniasis Diseases 0.000 claims description 2
- 241000223109 Trypanosoma cruzi Species 0.000 claims description 2
- 208000034784 Tularaemia Diseases 0.000 claims description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 2
- 208000010097 Unknown Primary Neoplasms Diseases 0.000 claims description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 201000005969 Uveal melanoma Diseases 0.000 claims description 2
- 206010046980 Varicella Diseases 0.000 claims description 2
- 208000005181 Varicella Zoster Virus Infection Diseases 0.000 claims description 2
- 241000700647 Variola virus Species 0.000 claims description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 2
- 241000607598 Vibrio Species 0.000 claims description 2
- 241000607272 Vibrio parahaemolyticus Species 0.000 claims description 2
- 208000028227 Viral hemorrhagic fever Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 201000006449 West Nile encephalitis Diseases 0.000 claims description 2
- 206010057293 West Nile viral infection Diseases 0.000 claims description 2
- 208000027207 Whipple disease Diseases 0.000 claims description 2
- 208000029977 White Dot Syndromes Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 208000003152 Yellow Fever Diseases 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 claims description 2
- 206010000269 abscess Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 208000004064 acoustic neuroma Diseases 0.000 claims description 2
- 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 claims description 2
- 201000007691 actinomycosis Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 201000007434 ampulla of Vater carcinoma Diseases 0.000 claims description 2
- 206010002022 amyloidosis Diseases 0.000 claims description 2
- 201000007538 anal carcinoma Diseases 0.000 claims description 2
- 201000004270 anal gland adenocarcinoma Diseases 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 201000010645 angiostrongyliasis Diseases 0.000 claims description 2
- 208000005067 anisakiasis Diseases 0.000 claims description 2
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 2
- 206010003230 arteritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims description 2
- 201000008680 babesiosis Diseases 0.000 claims description 2
- 201000009904 bacterial meningitis Diseases 0.000 claims description 2
- 208000007456 balantidiasis Diseases 0.000 claims description 2
- 201000005389 breast carcinoma in situ Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 2
- 201000002143 bronchus adenoma Diseases 0.000 claims description 2
- 208000002458 carcinoid tumor Diseases 0.000 claims description 2
- 208000011825 carcinoma of the ampulla of vater Diseases 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 201000007335 cerebellar astrocytoma Diseases 0.000 claims description 2
- 208000030239 cerebral astrocytoma Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000019065 cervical carcinoma Diseases 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 201000010354 chronic purulent otitis media Diseases 0.000 claims description 2
- 201000003486 coccidioidomycosis Diseases 0.000 claims description 2
- 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 claims description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 2
- 201000002641 cyclosporiasis Diseases 0.000 claims description 2
- 201000008167 cystoisosporiasis Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 208000025729 dengue disease Diseases 0.000 claims description 2
- 201000006827 desmoid tumor Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000018345 drug-induced vasculitis Diseases 0.000 claims description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims description 2
- 201000007273 ductal carcinoma in situ Diseases 0.000 claims description 2
- 210000001198 duodenum Anatomy 0.000 claims description 2
- 208000000292 ehrlichiosis Diseases 0.000 claims description 2
- 201000000107 encephalitozoonosis Diseases 0.000 claims description 2
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 2
- 206010014881 enterobiasis Diseases 0.000 claims description 2
- 230000002327 eosinophilic effect Effects 0.000 claims description 2
- 208000001606 epiglottitis Diseases 0.000 claims description 2
- 208000020612 escherichia coli infection Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 208000005098 feline infectious peritonitis Diseases 0.000 claims description 2
- 208000037957 feline spongiform encephalopathy Diseases 0.000 claims description 2
- 208000028149 female reproductive system neoplasm Diseases 0.000 claims description 2
- 230000003328 fibroblastic effect Effects 0.000 claims description 2
- 201000008825 fibrosarcoma of bone Diseases 0.000 claims description 2
- 235000020932 food allergy Nutrition 0.000 claims description 2
- 201000007487 gallbladder carcinoma Diseases 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 201000010476 glaucomatocyclitic crisis Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000001786 gonorrhea Diseases 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 201000005648 hantavirus pulmonary syndrome Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 208000029080 human African trypanosomiasis Diseases 0.000 claims description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 2
- 230000002267 hypothalamic effect Effects 0.000 claims description 2
- 230000007813 immunodeficiency Effects 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 201000006334 interstitial nephritis Diseases 0.000 claims description 2
- 201000009019 intestinal benign neoplasm Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 claims description 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 claims description 2
- 208000001875 irritant dermatitis Diseases 0.000 claims description 2
- 230000000622 irritating effect Effects 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 208000022013 kidney Wilms tumor Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 201000011486 lichen planus Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000011059 lobular neoplasia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 208000030883 malignant astrocytoma Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 201000006812 malignant histiocytosis Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000006512 mast cell neoplasm Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 210000000716 merkel cell Anatomy 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 206010063344 microscopic polyangiitis Diseases 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
- 201000004237 myringitis bullosa hemorrhagica Diseases 0.000 claims description 2
- 208000037830 nasal cancer Diseases 0.000 claims description 2
- 230000002956 necrotizing effect Effects 0.000 claims description 2
- 230000009826 neoplastic cell growth Effects 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 208000007538 neurilemmoma Diseases 0.000 claims description 2
- 201000002575 ocular melanoma Diseases 0.000 claims description 2
- 208000003692 opisthorchiasis Diseases 0.000 claims description 2
- 201000005443 oral cavity cancer Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 201000006958 oropharynx cancer Diseases 0.000 claims description 2
- 230000000010 osteolytic effect Effects 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims description 2
- 210000004197 pelvis Anatomy 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 208000015385 phacoanaphylactic uveitis Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 231100000572 poisoning Toxicity 0.000 claims description 2
- 230000000607 poisoning effect Effects 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 2
- 208000009305 pseudorabies Diseases 0.000 claims description 2
- 201000009259 purulent acute otitis media Diseases 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 230000005810 radionecrosis Effects 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 208000020615 rectal carcinoma Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 208000009169 relapsing polychondritis Diseases 0.000 claims description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 208000009146 rhinoscleroma Diseases 0.000 claims description 2
- 235000019515 salmon Nutrition 0.000 claims description 2
- 206010039447 salmonellosis Diseases 0.000 claims description 2
- 208000005687 scabies Diseases 0.000 claims description 2
- 206010039667 schwannoma Diseases 0.000 claims description 2
- 208000013223 septicemia Diseases 0.000 claims description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 claims description 2
- 201000005113 shigellosis Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 201000008261 skin carcinoma Diseases 0.000 claims description 2
- 201000002612 sleeping sickness Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 201000010321 spongiotic dermatitis Diseases 0.000 claims description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 208000008732 thymoma Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 201000006134 tongue cancer Diseases 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 208000003982 trichinellosis Diseases 0.000 claims description 2
- 201000007588 trichinosis Diseases 0.000 claims description 2
- 201000002311 trypanosomiasis Diseases 0.000 claims description 2
- 208000025301 tympanitis Diseases 0.000 claims description 2
- 208000026517 ureter neoplasm Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000023747 urothelial carcinoma Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 208000010531 varicella zoster infection Diseases 0.000 claims description 2
- 201000008195 viral laryngitis Diseases 0.000 claims description 2
- 210000001260 vocal cord Anatomy 0.000 claims description 2
- 230000001755 vocal effect Effects 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 abstract description 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract description 2
- 150000003230 pyrimidines Chemical class 0.000 abstract description 2
- JUXWUYWPUDKPSD-UHFFFAOYSA-N pyrazolo[1,5-a][1,3,5]triazine Chemical compound N1=CN=CN2N=CC=C21 JUXWUYWPUDKPSD-UHFFFAOYSA-N 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 description 179
- 238000003786 synthesis reaction Methods 0.000 description 179
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 156
- 238000006243 chemical reaction Methods 0.000 description 150
- 239000000243 solution Substances 0.000 description 142
- 239000011734 sodium Substances 0.000 description 91
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 89
- 239000011541 reaction mixture Substances 0.000 description 87
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 82
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 82
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- 235000019439 ethyl acetate Nutrition 0.000 description 78
- 239000003921 oil Substances 0.000 description 65
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 65
- 239000007787 solid Substances 0.000 description 65
- 239000012267 brine Substances 0.000 description 64
- 239000000843 powder Substances 0.000 description 57
- 239000012043 crude product Substances 0.000 description 54
- 239000000725 suspension Substances 0.000 description 45
- 239000012044 organic layer Substances 0.000 description 38
- 239000000706 filtrate Substances 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 239000012299 nitrogen atmosphere Substances 0.000 description 34
- 239000000460 chlorine Chemical group 0.000 description 29
- 239000000284 extract Substances 0.000 description 29
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 28
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 28
- 229920006395 saturated elastomer Polymers 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 239000008346 aqueous phase Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 22
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 20
- 231100000747 viability assay Toxicity 0.000 description 20
- 238000003026 viability measurement method Methods 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 0 N#CC[C@@](C1)*=C(c2ccccc22)N1C2=O Chemical compound N#CC[C@@](C1)*=C(c2ccccc22)N1C2=O 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 238000000746 purification Methods 0.000 description 13
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 11
- 229910019213 POCl3 Inorganic materials 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- 239000012065 filter cake Substances 0.000 description 11
- 108091000080 Phosphotransferase Proteins 0.000 description 10
- 229910000024 caesium carbonate Inorganic materials 0.000 description 10
- 102000020233 phosphotransferase Human genes 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 8
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 7
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 7
- 241000400611 Eucalyptus deanei Species 0.000 description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 7
- 229940045348 brown mixture Drugs 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 6
- 102100032864 General transcription factor IIH subunit 2 Human genes 0.000 description 6
- 101000655398 Homo sapiens General transcription factor IIH subunit 2 Proteins 0.000 description 6
- 101000655402 Homo sapiens General transcription factor IIH subunit 5 Proteins 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- 108010072268 cyclin-dependent kinase-activating kinase Proteins 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 102100036883 Cyclin-H Human genes 0.000 description 5
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 5
- 101000666405 Homo sapiens General transcription factor IIH subunit 1 Proteins 0.000 description 5
- 101000655391 Homo sapiens General transcription factor IIH subunit 3 Proteins 0.000 description 5
- 101000655406 Homo sapiens General transcription factor IIH subunit 4 Proteins 0.000 description 5
- 102000001253 Protein Kinase Human genes 0.000 description 5
- 102000009572 RNA Polymerase II Human genes 0.000 description 5
- 108010009460 RNA Polymerase II Proteins 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 5
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 5
- 108060006633 protein kinase Proteins 0.000 description 5
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 4
- GDHXJNRAJRCGMX-UHFFFAOYSA-N 2-fluorobenzonitrile Chemical compound FC1=CC=CC=C1C#N GDHXJNRAJRCGMX-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229940125888 CDK7 inhibitor Drugs 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 101710149951 Protein Tat Proteins 0.000 description 4
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- OBJNFLYHUXWUPF-IZZDOVSWSA-N n-[3-[[5-chloro-4-(1h-indol-3-yl)pyrimidin-2-yl]amino]phenyl]-4-[[(e)-4-(dimethylamino)but-2-enoyl]amino]benzamide Chemical compound C1=CC(NC(=O)/C=C/CN(C)C)=CC=C1C(=O)NC1=CC=CC(NC=2N=C(C(Cl)=CN=2)C=2C3=CC=CC=C3NC=2)=C1 OBJNFLYHUXWUPF-IZZDOVSWSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 3
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000016736 Cyclin Human genes 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 108010068237 Cyclin H Proteins 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 229940125833 compound 23 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000000021 kinase assay Methods 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- IHCHOVVAJBADAH-UHFFFAOYSA-N n-[2-hydroxy-4-(1h-pyrazol-4-yl)phenyl]-6-methoxy-3,4-dihydro-2h-chromene-3-carboxamide Chemical compound C1C2=CC(OC)=CC=C2OCC1C(=O)NC(C(=C1)O)=CC=C1C=1C=NNC=1 IHCHOVVAJBADAH-UHFFFAOYSA-N 0.000 description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
- KOFLVDBWRHFSAB-UHFFFAOYSA-N 1,2,4,5-tetrahydro-1-(phenylmethyl)-5,9b(1',2')-benzeno-9bh-benz(g)indol-3(3ah)-one Chemical compound C1C(C=2C3=CC=CC=2)C2=CC=CC=C2C23C1C(=O)CN2CC1=CC=CC=C1 KOFLVDBWRHFSAB-UHFFFAOYSA-N 0.000 description 2
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 2
- KYFXPHPBTUJULU-UHFFFAOYSA-N 2-(2-methoxyanilino)-2-(2-phenylmethoxyphenyl)acetonitrile Chemical compound COC1=CC=CC=C1NC(C#N)C1=CC=CC=C1OCC1=CC=CC=C1 KYFXPHPBTUJULU-UHFFFAOYSA-N 0.000 description 2
- UOXJNGFFPMOZDM-UHFFFAOYSA-N 2-[di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid Chemical compound CC(C)N(C(C)C)CCSP(C)(O)=O UOXJNGFFPMOZDM-UHFFFAOYSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- FJXJAAFKONAPKR-UHFFFAOYSA-N 4-methoxy-2-nitrobenzo[e][1]benzofuran Chemical compound COC1=CC2=CC=CC=C2C2=C1OC([N+]([O-])=O)=C2 FJXJAAFKONAPKR-UHFFFAOYSA-N 0.000 description 2
- SDMXLAZIFYYECU-UHFFFAOYSA-N 4-methoxycyclohexan-1-amine Chemical compound COC1CCC(N)CC1 SDMXLAZIFYYECU-UHFFFAOYSA-N 0.000 description 2
- YBGOLOJQJWLUQP-UHFFFAOYSA-O 7-(dimethylamino)-4-hydroxy-3-oxophenoxazin-10-ium-1-carboxylic acid Chemical compound OC(=O)C1=CC(=O)C(O)=C2OC3=CC(N(C)C)=CC=C3[NH+]=C21 YBGOLOJQJWLUQP-UHFFFAOYSA-O 0.000 description 2
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 102100040428 Chitobiosyldiphosphodolichol beta-mannosyltransferase Human genes 0.000 description 2
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102100035184 General transcription and DNA repair factor IIH helicase subunit XPD Human genes 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 101000891557 Homo sapiens Chitobiosyldiphosphodolichol beta-mannosyltransferase Proteins 0.000 description 2
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 229910017852 NH2NH2 Inorganic materials 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 2
- 102000050257 X-Linked Inhibitor of Apoptosis Human genes 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000006369 cell cycle progression Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000007824 enzymatic assay Methods 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 230000006951 hyperphosphorylation Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- MVUNGZMGWJXPIM-UHFFFAOYSA-N tert-butyl n-(4-methylpiperidin-4-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1(C)CCNCC1 MVUNGZMGWJXPIM-UHFFFAOYSA-N 0.000 description 2
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- NOYASZMZIBFFNZ-UHFFFAOYSA-N (2-bromophenyl)methanamine Chemical compound NCC1=CC=CC=C1Br NOYASZMZIBFFNZ-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 1
- WAUGGYPDCQZJKK-UHFFFAOYSA-N 1h-pyrrol-3-amine Chemical compound NC=1C=CNC=1 WAUGGYPDCQZJKK-UHFFFAOYSA-N 0.000 description 1
- PTHDBHDZSMGHKF-ZETCQYMHSA-N 2-[(2s)-piperidin-2-yl]ethanol Chemical compound OCC[C@@H]1CCCCN1 PTHDBHDZSMGHKF-ZETCQYMHSA-N 0.000 description 1
- HTFNVAVTYILUCF-UHFFFAOYSA-N 2-[2-ethoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino]-5-methyl-11-methylsulfonylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(c2n1)S(C)(=O)=O)C(=O)N1CCC(CC1)N1CCN(C)CC1 HTFNVAVTYILUCF-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 1
- MWFMGBPGAXYFAR-UHFFFAOYSA-N 2-hydroxy-2-methylpropanenitrile Chemical compound CC(C)(O)C#N MWFMGBPGAXYFAR-UHFFFAOYSA-N 0.000 description 1
- CHZCERSEMVWNHL-UHFFFAOYSA-N 2-hydroxybenzonitrile Chemical compound OC1=CC=CC=C1C#N CHZCERSEMVWNHL-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XXGQGFIISHCNSE-UHFFFAOYSA-N 4-(trifluoromethoxy)piperidine Chemical compound FC(F)(F)OC1CCNCC1 XXGQGFIISHCNSE-UHFFFAOYSA-N 0.000 description 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 1
- IMLXLGZJLAOKJN-UHFFFAOYSA-N 4-aminocyclohexan-1-ol Chemical compound NC1CCC(O)CC1 IMLXLGZJLAOKJN-UHFFFAOYSA-N 0.000 description 1
- OYHQAXYDSYSGEI-UHFFFAOYSA-N 4-ethoxypiperidine Chemical compound CCOC1CCNCC1 OYHQAXYDSYSGEI-UHFFFAOYSA-N 0.000 description 1
- VIBZEOYMXOCRTD-UHFFFAOYSA-N 4-propan-2-yloxycyclohexan-1-amine Chemical compound CC(C)OC1CCC(N)CC1 VIBZEOYMXOCRTD-UHFFFAOYSA-N 0.000 description 1
- RKGXJBAAWCGBQA-UHFFFAOYSA-N 4-propan-2-yloxypiperidine Chemical compound CC(C)OC1CCNCC1 RKGXJBAAWCGBQA-UHFFFAOYSA-N 0.000 description 1
- QDDQSSZZYNCVHC-UHFFFAOYSA-N 5-[(4-tert-butylphenoxy)carbonylamino]-2-hydroxybenzoic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1OC(=O)NC1=CC=C(O)C(C(O)=O)=C1 QDDQSSZZYNCVHC-UHFFFAOYSA-N 0.000 description 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WWGUAFRTAYMNHU-UHFFFAOYSA-N Benzyl 4-piperidinylcarbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1CCNCC1 WWGUAFRTAYMNHU-UHFFFAOYSA-N 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- NFZVHIAOXWYPLX-UHFFFAOYSA-N C(C)(CC)OC(=O)N=C=S Chemical compound C(C)(CC)OC(=O)N=C=S NFZVHIAOXWYPLX-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- XOWZKYHDUXOACL-UHFFFAOYSA-O CC(C)(C(CC1)CN1c1c(C[NH3+])c(Cl)ccc1)O Chemical compound CC(C)(C(CC1)CN1c1c(C[NH3+])c(Cl)ccc1)O XOWZKYHDUXOACL-UHFFFAOYSA-O 0.000 description 1
- FXPKMXXGDZJZBE-ZDUSSCGKSA-N CC(C)OC(C)(C)[C@@H](CC1)CN1c1cccc(Cl)c1C#N Chemical compound CC(C)OC(C)(C)[C@@H](CC1)CN1c1cccc(Cl)c1C#N FXPKMXXGDZJZBE-ZDUSSCGKSA-N 0.000 description 1
- VAAJGCDAYQIYPO-UHFFFAOYSA-N CC(C)c(cn[n]1c(Cl)c2)c1nc2Cl Chemical compound CC(C)c(cn[n]1c(Cl)c2)c1nc2Cl VAAJGCDAYQIYPO-UHFFFAOYSA-N 0.000 description 1
- UTLBOEASLGRBLB-UHFFFAOYSA-N CC(C)c(cn[n]1c(NCc(cccc2)c2-c2ccc(cccc3)c3n2)c2)c1nc2Cl Chemical compound CC(C)c(cn[n]1c(NCc(cccc2)c2-c2ccc(cccc3)c3n2)c2)c1nc2Cl UTLBOEASLGRBLB-UHFFFAOYSA-N 0.000 description 1
- HGOUUJCRFCKLJO-UHFFFAOYSA-N CC(C)c(cn[n]1c(NCc(cccc2)c2-c2nc(cccc3)c3cc2)c2)c1nc2N(CC1)CCC1N Chemical compound CC(C)c(cn[n]1c(NCc(cccc2)c2-c2nc(cccc3)c3cc2)c2)c1nc2N(CC1)CCC1N HGOUUJCRFCKLJO-UHFFFAOYSA-N 0.000 description 1
- RLFAIKSBXKSVKV-UHFFFAOYSA-N CC(C)c(cn[n]1c(NCc2ccccc2-[n]2nccc2)n2)c1nc2S=O Chemical compound CC(C)c(cn[n]1c(NCc2ccccc2-[n]2nccc2)n2)c1nc2S=O RLFAIKSBXKSVKV-UHFFFAOYSA-N 0.000 description 1
- NSGHBAXOPRCKNH-UHFFFAOYSA-N CC(C)c1c2nc(C3CCNCC3)nc(NCc3ccccc3-[n]3nccc3)[n]2nc1 Chemical compound CC(C)c1c2nc(C3CCNCC3)nc(NCc3ccccc3-[n]3nccc3)[n]2nc1 NSGHBAXOPRCKNH-UHFFFAOYSA-N 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- 102100030933 CDK-activating kinase assembly factor MAT1 Human genes 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- DBXCIDMJJODDQR-UHFFFAOYSA-N CN(CC1)Cc2c1nccc2 Chemical compound CN(CC1)Cc2c1nccc2 DBXCIDMJJODDQR-UHFFFAOYSA-N 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- HQNBJNDMPLEUDS-UHFFFAOYSA-N Cc1cnc[n]1C Chemical compound Cc1cnc[n]1C HQNBJNDMPLEUDS-UHFFFAOYSA-N 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- 102000002554 Cyclin A Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010008945 General Transcription Factors Proteins 0.000 description 1
- 102000006580 General Transcription Factors Human genes 0.000 description 1
- 102100031885 General transcription and DNA repair factor IIH helicase subunit XPB Human genes 0.000 description 1
- 102100032865 General transcription factor IIH subunit 5 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 101000583935 Homo sapiens CDK-activating kinase assembly factor MAT1 Proteins 0.000 description 1
- 101000713120 Homo sapiens Cyclin-H Proteins 0.000 description 1
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- XPTAYRHLHAFUOS-UHFFFAOYSA-N N#Cc(c(F)ccc1)c1Cl Chemical compound N#Cc(c(F)ccc1)c1Cl XPTAYRHLHAFUOS-UHFFFAOYSA-N 0.000 description 1
- BNVCOVNARIQBEO-UHFFFAOYSA-N N#Cc1ccccc1Oc1ccccc1 Chemical compound N#Cc1ccccc1Oc1ccccc1 BNVCOVNARIQBEO-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- ZCIQSCUWRMIBNA-UHFFFAOYSA-N NCc1ccccc1-[n]1ncc(N2CCOCC2)c1 Chemical compound NCc1ccccc1-[n]1ncc(N2CCOCC2)c1 ZCIQSCUWRMIBNA-UHFFFAOYSA-N 0.000 description 1
- WXCFCNCGPYJALB-UHFFFAOYSA-N NCc1ccccc1Oc1ccccc1 Chemical compound NCc1ccccc1Oc1ccccc1 WXCFCNCGPYJALB-UHFFFAOYSA-N 0.000 description 1
- 229910017849 NH2—NH2 Inorganic materials 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100023059 Nuclear factor NF-kappa-B p100 subunit Human genes 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N O=C(c1c2cccc1)NC2=O Chemical compound O=C(c1c2cccc1)NC2=O XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- DUILGEYLVHGSEE-SSDOTTSWSA-N O=C(c1ccccc11)N(C[C@H]2OC2)C1=O Chemical compound O=C(c1ccccc11)N(C[C@H]2OC2)C1=O DUILGEYLVHGSEE-SSDOTTSWSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 102100020814 Sequestosome-1 Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010083256 Transcription Factor TFIIH Proteins 0.000 description 1
- 102000006288 Transcription Factor TFIIH Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- PRAYXGYYVXRDDW-LURJTMIESA-N [(2s)-piperidin-2-yl]methanol Chemical compound OC[C@@H]1CCCCN1 PRAYXGYYVXRDDW-LURJTMIESA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940091181 aconitic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- MJSHDCCLFGOEIK-UHFFFAOYSA-N benzyl (2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)OCC1=CC=CC=C1 MJSHDCCLFGOEIK-UHFFFAOYSA-N 0.000 description 1
- KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 108010089576 carboxy-terminal domain kinase Proteins 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- VKONPUDBRVKQLM-UHFFFAOYSA-N cyclohexane-1,4-diol Chemical compound OC1CCC(O)CC1 VKONPUDBRVKQLM-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 229950011470 enantate Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- BDTDECDAHYOJRO-UHFFFAOYSA-N ethyl n-(sulfanylidenemethylidene)carbamate Chemical compound CCOC(=O)N=C=S BDTDECDAHYOJRO-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000024697 human cytomegalovirus infection Diseases 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- LVCDXCQFSONNDO-UHFFFAOYSA-N n-benzylhydroxylamine Chemical compound ONCC1=CC=CC=C1 LVCDXCQFSONNDO-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YLWUSMHZABTZGP-UHFFFAOYSA-N n-piperidin-4-ylacetamide Chemical compound CC(=O)NC1CCNCC1 YLWUSMHZABTZGP-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 108091008820 oncogenic transcription factors Proteins 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- IPBPLHNLRKRLPJ-UHFFFAOYSA-N oxan-4-ylmethanamine Chemical compound NCC1CCOCC1 IPBPLHNLRKRLPJ-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- UIJXHKXIOCDSEB-MRVPVSSYSA-N tert-butyl (3r)-3-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](O)C1 UIJXHKXIOCDSEB-MRVPVSSYSA-N 0.000 description 1
- NSILYQWHARROMG-QMMMGPOBSA-N tert-butyl (3s)-3-(hydroxymethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN[C@H](CO)C1 NSILYQWHARROMG-QMMMGPOBSA-N 0.000 description 1
- MTMBHUYOIZWQAJ-UHFFFAOYSA-N tert-butyl 2-(aminomethyl)morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOC(CN)C1 MTMBHUYOIZWQAJ-UHFFFAOYSA-N 0.000 description 1
- FMLPQHJYUZTHQS-UHFFFAOYSA-N tert-butyl 3-methylpiperazine-1-carboxylate Chemical compound CC1CN(C(=O)OC(C)(C)C)CCN1 FMLPQHJYUZTHQS-UHFFFAOYSA-N 0.000 description 1
- KLKBCNDBOVRQIJ-UHFFFAOYSA-N tert-butyl 4-(aminomethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CN)CC1 KLKBCNDBOVRQIJ-UHFFFAOYSA-N 0.000 description 1
- CTEDVGRUGMPBHE-UHFFFAOYSA-N tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CO)CC1 CTEDVGRUGMPBHE-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- IMFPSYLOYADSFR-UHFFFAOYSA-N tert-butyl 4-piperidin-4-ylpiperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1CCNCC1 IMFPSYLOYADSFR-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IYHJNCQAADULQE-UHFFFAOYSA-N tert-butyl n-(morpholin-2-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1CNCCO1 IYHJNCQAADULQE-UHFFFAOYSA-N 0.000 description 1
- VHYXAWLOJGIJPC-UHFFFAOYSA-N tert-butyl n-(piperidin-4-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCNCC1 VHYXAWLOJGIJPC-UHFFFAOYSA-N 0.000 description 1
- QBENUNRDGNUPQJ-UHFFFAOYSA-N tert-butyl n-[(4-fluoropiperidin-4-yl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1(F)CCNCC1 QBENUNRDGNUPQJ-UHFFFAOYSA-N 0.000 description 1
- ZVUCOORWSKRJII-UHFFFAOYSA-N tert-butyl n-[(4-hydroxypiperidin-4-yl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1(O)CCNCC1 ZVUCOORWSKRJII-UHFFFAOYSA-N 0.000 description 1
- WUOQXNWMYLFAHT-UHFFFAOYSA-N tert-butyl n-piperidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCCNC1 WUOQXNWMYLFAHT-UHFFFAOYSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006407 thiazinanyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000007484 viral process Effects 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the present invention relates to pyrazolo[l,5-a][l,3,5]triazine and pyrazolo[l,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[l,5-a][l,3,5]triazine and pyrazolo[ 1,5 -a] pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.
- CDK family members that trigger passage through the cell cycle are being considered as attractive therapeutic targets, especially for cancer.
- CDK family members that control other processes such as transcription and RNA processing have caught less attention so far, although experimental evidence for their involvement in different pathological processes is emerging.
- CDK/cyclin complexes also have been identified as conserved components of the RNA polymerase II (Pol II) transcriptional machinery ( Bregman et ah, 2000, Front Biosci. 5:244-257).
- RNA polymerase II RNA polymerase II
- CDK7 has consolidated kinase activities, regulating both the cell cycle progression and transcription ( Desai et ah, 1995, Mol. Cell Biol. 15, 345-350).
- the general transcription factor TFIIH purified from mammalian cells consists of ten subunits, seven of which (p62, p52, p44, p34, XPD, XPB, and TTDA) form the core complex. Three subunits (cyclin H, MAT1, and CDK7) from the CDK-activating kinase (CAK), which is linked to TFIIH’s core via the XPD (ATP-dependent helicase) subunit of complex.
- CAK CDK-activating kinase
- CDK7 phosphorylates the C-terminal domain (CTD) of Pol II at serine 5 and 7 (Akhtar et ah, 2009, Mol. Cell 34, 387-393) as well as other transcription factors controlling the initiation-to-elongation transition (Larochelle et al., 2012, Nat. Strut. Mol. Biol. 19, 1108- 1115 Therefore CDK7 is essential factor for transcription process, which suggests that CDK7 is a target for cancer therapy, especially transcription addicted cancer. CDK7 has long been asserted as having an essential role in cellular metabolism and viability.
- Transcriptional CDK inhibitors down-regulate a large number of short-lived anti-apoptotic proteins, such as the anti-apoptotic proteins myeloid cell leukemia-l (Mcl-l), B-cell lymphoma extra-long (Bcl-xL) and XIAP (X-linked IAP), D-cyclins, c-Myc, Mdm-2 (leading to p53 stabilization), p2l wafl proteins whose transcription is mediated by nuclear factor-kappa B (NF-kB) and hypoxia-induced VEGF ⁇ Shapiro GL 2006, J Clin Oncol; 24(11): 1770-83).
- Mcl-l myeloid cell leukemia-l
- Bcl-xL B-cell lymphoma extra-long
- XIAP X-linked IAP
- D-cyclins c-Myc
- Mdm-2 leading to p53 stabilization
- p2l wafl proteins whose
- CDK7 as regulator of general transcription and CDK7 is a therapeutic target for treatment of many diseases and syndromes are associated with mutations in regulatory regions and in transcription factors, cofactors, chromatin regulators and noncoding RNAs. These mutations can contribute to cancer, autoimmunity, neurological disorders, developmental syndromes, diabetes, cardiovascular disease, and obesity, among others. Some transcription factors control RNA polymerase II pause release and elongation and, when their expression or function is altered, can produce aggressive tumor cells (c-Myc) or some forms of autoimmunity (AIRE) ⁇ Tong Ihn Lee and Richard A. Young, Cell, 2013, 152:1237-1251).
- c-Myc c-Myc
- AIRE autoimmunity
- CDK7 is a therapeutic target for treatment of disease like inflammation, virus replication such as HIV, EBV, cancer and cardiac hypertrophy.
- HIV-l gene expression is regulatory by a viral transactivator protein (Tat) which induces transcriptional elongation of HIV-l long tandem repeat. This induction requires hyperphosphorylation of the C-terminal domain repeat of RNA polymerase II.
- Tat stimulates CTD kinases associated with general transcription factors of the promoter complex, specifically TFIIH-associated CDK7 (Nekhai et al.; Biochem J. (2002) 364, 649-657).
- the inventors of US 615968 also described that Tat binds to CDK7 and that this interaction increase the ability of CAK to phosphorylate CTD.
- the authors of US 615968 further disclose that the transcriptional activation by Tat is dependent upon the kinase activity of CDK7. Additionally, Young Kyeung Kim and colleagues conclude that the recruitment and activation of TFIIH represents a rate-limiting step for the emergence of HIV from latency (Young Kyeung Kim, EMBO (2006) 25, 3596-3604).
- MAT- 1/cyclin H are upregulated during Human cytomegalovirus infection.
- kinase activities of CDK7 and CDK9 Troprakar et al., Journal of Virology, 2005, 79; 15477-15493.
- antiviral drugs target viral proteins. These have the disadvantage that viruses often develop resistance against these drugs. Antiviral drugs targeting cellular proteins essential for viral process, like CDK7, could bypass this disadvantage. These drugs may further be effective in treating several unrelated viruses and their effects should be additive to traditional antiviral agents. Inhibitors of CDK7, which has its dual function of CDK-activating kinase and transcription regulation is very effective in the treatment of several viruses.
- the present invention relates to pyrazolo-triazine or pyrazolo-pyrimidine compounds which are defined by general formula I
- X is, independently at each occurrence, selected from CH and N;
- Q is, independently at each occurrence, selected from the group consisting of C3-C8 cycloalkyl, aryl, heteroaryl, heterocyclyl, and C1-C6 alkyl, wherein C1-C6 alkyl is substituted with one or two of OR 5 , -N(R 5 )R 5 , aryl, heteroaryl and heterocyclyl,
- C3-C8 cycloalkyl can be substituted with one or two of R 3 and R 4 and -(CO)R 5
- heterocyclyl can be substituted with one or two of R 3 and R 4 and -(CO)R 5 aryl or heteroaryl substituted with one or two of C1-C6 alkyl, -OR 5 , -N(R 5 )R 5 , - (CO)R 5 , halogen, heteroaryl and heterocyclyl;
- R 1 is, at each occurrence, independently selected from the group consisting of hydrogen and methyl
- R 5 is, at each occurrence, independently selected from the group consisting of hydrogen, Cl- C6 alkyl, C3-C8 cycloalkyl, C1-C3 haloalkyl, heteroaryl, heterocyclyl, heteroaryl substituted with one or two of halogen, -OR 11 , -N(R 11 )R 11 , C1-C6 alkyl and C1-C6 alkyl substituted with -OH or -NH 2 , heterocyclyl substituted with one or two of halogen, -OR 11 , -N(R u )R n , C1-C6 alkyl and C1-C6 alkyl substituted with -OH or -NH 2 ;
- Z is any structure of the following group A;
- X is, independently at each occurrence, selected from CR and N;
- X 2 is, independently at each occurrence, selected from CR 25 and N;
- R 9 is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, -OR 5 , -CN, C3-C10 cycloalkyl, C3-C10 heterocyclyl and C1-C6 alkyl substituted with -OH or -OR 5 ;
- R 11 is, at each occurrence, independently selected from the group consisting of hydrogen, Cl- C6 alkyl and C3-C10 cycloalkyl;
- R° is, at each occurrence, independently selected from the group consisting of hydrogen, Cl- C6 alkyl, C1-C6 alkyl substituted with -CN, -OH, -OR 5 , -NH 2 , -NHR 5 or -N(R 5 )R 5 and C3- C10 cycloalkyl;
- R 17 , R 18 , R 19 and R 20 are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, C6-C10 aryl, e.g.
- R 21 is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 heterocyclyl, C1-C3 haloalkyl, aryl, phenyl, benzyl, C1-C6 alkyl substituted with -CN, -OH, -OR 5 , -NH 2 , -NHR 5 or -N(R 5 )R 5 , aryl substituted with halogen or C1-C3 haloalkyl, C3-C10 heteroaryl substituted with one to four halogens or C1-C3 alkyl and C3-C10 heterocyclyl substituted with R 4 ;
- R 22 and R 23 are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, -OH, -OR 5 , -CN and C1-C6 alkyl substituted with -OH, -OR 5 or -NHR 9 ;
- R 24 and R 25 are, at each occurrence, independently selected from the group consisting of
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is absent
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is N(R 5 )R 5
- R 4 is H
- R 5 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H
- R 6 is not lH-pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is CHs
- R 4 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 6 is not CH 3 , Cl or lH-pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is CH 3
- R 4 is H
- X is N
- Z is phenyl
- R 6 is OR 12
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 12 is not phenyl, CH(CH 3 ) 2 , CH 2 CH 3 or CH 3 ;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is C3 ⁇ 4
- R 4 is H
- X is N
- Z is phenyl
- R 6 is Cl
- R 7 is H
- R 8 is H and R 9 is H
- R 10 is not Cl
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is CH 3
- R 4 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is Cl
- R 6 is not Cl
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is CHs
- R 4 is H
- X is N
- Z is phenyl
- R 6 is Cl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is not C3 ⁇ 4;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is CH 3
- R 4 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is Cl
- R 6 is not CH 3 ;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is CH 3
- R 4 is H
- X is N
- Z is phenyl
- R 6 is F
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is not F
- R 1 is H
- R 2 is CH(CFI 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is CH 3
- R 4 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is F
- R 6 is not F;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is CH 3
- R 4 is H
- X is N
- Z is phenyl
- R 6 is OR 12
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 12 is not CH 3 ;
- R 1 is H
- R 2 is CH(CFI 3 )2
- Q is heterocyclyl substituted with R 3 and R 4
- R 4 is H
- X is N
- Z is phenyl
- R 6 is lH-pyrazole
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 3 is not H;
- R 1 is FI
- R 2 is CH(CH 3 ) 2
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is N(R 5 )R 5
- R 4 is H
- R 5 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H
- R 6 is not lH-pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is H
- R 4 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H
- R 6 is not lH- pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is 0,
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is H
- R 4 is H
- X is N
- Z is phenyl
- R 6 is OR 12
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H
- R 12 is not CH(CH 3 ) 2 ;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is H
- R 4 is H
- X is N
- Z is phenyl
- R 6 is OR 12
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 12 is not CH 3 ;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is C3-C8 cycloalkyl substituted with R 3 and R 4
- R 3 is N(R 5 )R 5
- R 4 is H
- R 5 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 6 is not lH-pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is NH
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is H
- R 4 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 6 is not 1H- pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is NH
- Q is C3-C8 cycloalkyl substituted with R 3 and R 4
- R 3 is N(R 5 )R 5
- R 4 is H
- R 5 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H
- R 6 is not lH-pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is H
- R 4 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is F
- R 6 is not 1H- pyrazole
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is H
- R 4 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 6 is not 1H- pyr azole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is CH 3
- R 4 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H
- R 6 is not lH- pyrazole
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is H
- R 4 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H and R 10 is H
- then R 12 is not CH 3 ;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is CH 3
- R 4 is H
- X is N
- Z is phenyl
- R 6 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 7 is not Cl
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is CH 3
- R 4 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H
- R 10 is H
- R 12 is not CH 3 ;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q is C3-C8 cycloalkyl substituted with R 3 and R 4
- R 3 is N(R 5 )R 5
- R 4 is H
- R 5 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H
- R 10 is H, then R 12 is not CH 3 ;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is NH
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is H
- R 4 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H and R 10 is H
- R 12 is not CH 3 ;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is absent
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is N(R 5 )R 5
- R 4 is H
- R 5 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H
- R 10 is H
- R 12 is not CH 3 ;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is absent
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is N(R 5 )R 5
- R 4 is H
- R 5 is H
- X is N
- Z is phenyl
- R 6 is OR 12
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 12 is not CH 3 ;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is NH
- Q is C3-C8 cycloalkyl substituted with R 3 and R 4
- R 3 is N(R 5 )R 5
- R 4 is H
- R 5 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H and R 10 is H, then R 12 is not C3 ⁇ 4
- R 1 is C3 ⁇ 4
- R 2 is CH(CH 3 ) 2
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is H
- R 4 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H and R 10 is H, then R 12 is not CH 3 ;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- Q is heterocyclyl substituted with R 3 and R 4
- R 3 is N(R S )R 5
- R 4 is H
- R 5 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H and R 10 is H, then R 12 is not CH 3 ; or an enantiomer, stereoisomeric form, mixture of enantiomers, diastereomer, mixture of diastereomers, racemate of the above mentioned compounds, or a pharmaceutically acceptable salt thereof.
- R 1 is hydrogen and the compound has the general formula II
- the present invention relates to compounds having the general formula III
- Q 1 is either absent or independently, at each occurrence, selected from the group consisting of aryl, heteroaryl, heterocyclyl, aryl substituted with one or two of C1-C6 alkyl, -OR 5 , - N(R 5 )R 5 , and halogen; heteroaryl substituted with one or two of C1-C6 alkyl, -OR 5 , -N(R 5 )R 5 and halogen; and heterocyclyl substituted with one or two of R and R ;
- R 5 , R 9 and R 12 are as defined in claim 1 ;
- Y 1 is, independently at each occurrence, selected from CH, C(OH) and N;
- Y is, independently at each occurrence, selected from CH, CR , O andN;
- m is, independently at each occurrence, selected from 0, 1 and 2;
- n is, independently at each occurrence, selected from 0 and 1;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is absent
- Q 1 is absent
- L 2 is absent
- Y 1 is N
- Y 2 is CH
- m is 1
- n is 1
- R 29 is N(R 5 )R 5
- R 30 is H
- R 5 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H, then R 6 is not lH-pyrazole;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 1
- n 1
- R 29 is C3 ⁇ 4
- R 30 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 1
- n 1
- R 29 is C3 ⁇ 4
- R 30 is H
- X is N
- Z is phenyl
- R 6 is OR 12
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 12 is not phenyl, CH(CH 3 ) 2 , CH 2 CH 3 or CH 3 ;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 1
- n is 1
- R 29 is CH 3
- R 30 is H
- X is N
- Z is phenyl
- R 6 is Cl
- R 7 is H
- R 8 is H
- R 9 is H, then R 10 is not Cl;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 1
- n is 1
- R 29 is CH 3
- R 30 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is Cl
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 1
- n is 1
- R 29 is C3 ⁇ 4
- R 30 is H
- X is N
- Z is phenyl
- R 6 is Cl
- R 7 is H
- R 8 is H
- R 9 is H
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 1
- n 1
- R 29 is C3 ⁇ 4
- R 30 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is Cl
- R 1 is H, R 2 is CH(CH 3 ) , L 1 is O, Q 1 is absent, L 2 is absent, Y 1 is CH, Y 2 is N, m is 1, n is 1, R 29 is CH 3 , R 30 is H, X is N, Z is phenyl, R 6 is F, R 7 is H, R 8 is H and R 9 is H, then R 10 is not F;
- R 1 is H, R 2 is CH(CH 3 )2, L 1 is O, Q 1 is absent, L 2 is absent, Y 1 is CH, Y 2 is N, m is 1, n is 1, R 29 is CH 3 , R 30 is H, X is N, Z is phenyl, R 7 is H, R 8 is H, R 9 is H and R 10 is F, then R 6 is not F;
- R 1 is FI
- R 2 is CH(CH 3 ) 2
- Q 1 is absent
- L 2 is absent
- Y 1 is N
- Y 2 is N
- m is 1
- n is 1
- R 30 is H
- X is N
- Z is phenyl
- R 6 is lH-pyrazole
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H, then R 29 is not H;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- Q 1 is absent
- L 2 is absent
- Y 1 is N
- Y 2 is CH
- m is 1
- n is 1
- R 29 is N(R 5 )R 5
- R 30 is H
- R 5 is H
- R 30 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H, then R 6 is not IH-pyrazole;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 1
- n is 1
- R 29 is H
- R 30 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H, then R 6 is not lH-pyrazole;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 1
- n is 1
- R 29 is H
- R 30 is H
- X is N
- Z is phenyl
- R 6 is OR 12
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H, then R 12 is not CH(CH 3 ) 2 ;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 1
- n 0,
- R 29 is H
- R 30 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H, then R 6 is not lH-pyrazole;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 1
- n 0,
- R 29 is H
- R 30 is H
- X is N
- Z is phenyl
- R 6 is OR 12
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H, then R 12 is not CH(CH 3 ) 2 ;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is CH
- m 1, n is 1
- R 29 is N(R 5 )R 5
- R 30 is H
- R 5 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 H and R 10 is H
- R 6 is not lH-pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is NH
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m 1, n is 0,
- R 29 is H
- R 30 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H, then R is not lH-pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is absent
- Q 1 is absent
- L 2 is absent
- Y 1 is N
- Y 2 is CH
- m is 1
- n is 0,
- R 29 is N(R 5 )R 5
- R 30 is H
- R 5 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H
- R 6 is not lH-pyrazole
- R 1 is H
- R 2 is CH(CH ) 2
- L 1 is NH
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is CH
- m is 1
- n is 1
- R 29 is N(R 5 )R 5
- R 30 is H
- R 5 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H
- R 6 is not lH-pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is absent
- Q 1 is absent
- L 2 is absent
- Y 1 is N
- Y 2 is CH
- m 2
- n is 0,
- R 29 is N(R 5 )R 5
- R 30 is H
- R 5 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H
- R 6 is not lH-pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 2
- n is 0,
- R 29 is H
- R 30 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is F
- R 6 is not lH-pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 1
- n is 1
- R 29 is C3 ⁇ 4
- R 30 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 1 is C3 ⁇ 4, R 2 is CH(CH 3 ) 2 , L 1 is O, Q 1 is absent, L 2 is absent, Y 1 is CH, Y 2 is N, m is 1, n is 1, R 29 is CH 3 , R 30 is H, X is N, Z is phenyl, R 6 is OR 12 , R 7 is H, R 8 is H, R 9 is H and R 10 is H, then R 12 is not CH 3 ;
- R 1 is CH 3 , R 2 is CH(CH 3 ) 2 , L 1 is O, Q 1 is absent, L 2 is absent, Y 1 is CH, Y 2 is N, m is 1, n is 0, R 29 is H, R 30 is H, X is N, Z is phenyl, R 6 is OR 12 , R 7 is H, R 8 is H, R 9 is H and R 10 is H, then R 12 is not C3 ⁇ 4;
- R 1 is CH 3 , R 2 is CH(CH 3 ) 2 , L 1 is O, Q 1 is absent, L 2 is absent, Y 1 is CH, Y 2 is N, m is 1, n is 1, R 29 is H, R 30 is H, X is N, Z is phenyl, R 6 is OR 12 , R 7 is H, R 8 is H, R 9 is H and R 10 is H, then R 12 is not C3 ⁇ 4;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 2
- n is 0,
- R 29 is H
- R 30 is H
- X is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H, then R 6 is not lH-pyr azole;
- R 1 is C3 ⁇ 4
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 1
- n is 1
- R 29 is H
- R 30 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H and R 10 is H, then R 12 is not C3 ⁇ 4;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 1
- n is 1
- R 29 is CH 3
- R 30 is H
- X is N
- Z is phenyl
- R 6 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 1
- n 0,
- R 29 is H
- R 30 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H
- R 10 is H, then R 12 is not CH 3 ;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- m is 1
- n is 1
- R 29 is CH 3
- R 30 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H and R 10 is H, then R 12 is not CH 3 ;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is O
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is CH
- m is 1
- n is 1
- R 29 is N(R 5 )R 5
- R 30 is H
- R 5 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H and R 10 is H, then R 12 is not C3 ⁇ 4;
- R 1 is CH 3 , R 2 is CH(CH 3 ) 2 , L 1 is NH, Q 1 is absent, L 2 is absent, Y 1 is CH, Y 2 is N, m is 1, n is 0, R 29 is H, R 30 is H, X is N, Z is phenyl, R 6 is H, R 7 is OR 12 , R 8 is H, R 9 is H and R 10 is H, then R 12 is ot CH 3 ;
- R 1 is CH 3 , R 2 is CH(CH 3 ) 2 , L 1 is absent, Q 1 is absent, L 2 is absent, Y 1 is N, Y 2 is CH, m is 1, n is 0, R 29 is N(R 5 )R 5 , R 30 is H, R 5 is H, X is N, Z is phenyl, R 6 is H, R 7 is OR 12 , R 8 is H, R 9 is H and R 10 is H, then R 12 is not C3 ⁇ 4;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is absent
- Q 1 is absent
- L 2 is absent
- Y 1 is N
- Y 2 is CH
- m is 1
- n is 1
- R 29 is N(R 5 )R 5
- R 30 is H
- R 5 is H
- X is N
- Z is phenyl
- R 6 is OR 12
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H, then R 12 is not CH 3 ;
- R 1 is C3 ⁇ 4
- R 2 is CH(CH 3 ) 2
- L 1 is absent
- Q 1 is absent
- L 2 is absent
- Y 1 is N
- Y 2 is CH
- m is 1
- n is 1
- R 29 is N(R 5 )R 5
- R 30 is H
- R 5 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H and R 10 is H, then R 12 is not C3 ⁇ 4;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is NH
- Q 1 is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is CH
- m is 1
- n is 1
- R 29 is N(R 5 )R 5
- R 30 is H
- R 5 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H and R 10 is H, then R 12 is not C3 ⁇ 4;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- Q 1 is absent
- L 2 is absent
- Y 1 is N
- Y 2 is N
- m is 1
- n is 1
- R 29 is H
- R 30 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H and R 10 is H, then R 12 is not C3 ⁇ 4;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- Q 1 is absent
- L 2 is absent
- Y 1 is N
- Y 2 is CH
- m is 1
- n is 1
- R 29 is N(R 5 )R 5
- R 30 is H
- R 5 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H and R 10 is H, then R 12 is not C3 ⁇ 4;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- L 1 is absent
- Q 1 is absent
- L 2 is absent
- Y 1 is N
- Y 2 is CH
- m 2
- n is 0,
- R 29 is N(R 5 )R 5
- R 30 is H
- R 5 is H
- X is N
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H and R 10 is H, then R 12 is not CH 3 ; or an enantiomer, stereoisomeric form, mixture of enantiomers, diastereomer, mixture of diastereomers, racemate of the above mentioned compounds, or a pharmaceutically acceptable salt thereof.
- the present invention relates to compounds having the general formula la
- X is, independently at each occurrence, selected from CH and N;
- Y 1 is, independently at each occurrence, selected from CH, C(OH) andN;
- Y 2 is, independently at each occurrence, selected from CH, CR 4 , O and N; m is, independently at each occurrence, selected from 0, 1 and 2;
- n is, independently at each occurrence, selected from 0 and 1;
- Q is either absent or independently, at each occurrence, selected from the group consisting of heterocyclyl, C3-C6 heteroaryl, aryl, e.g. phenyl, aryl substituted with halogen;
- R 1 is, at each occurrence, independently selected from the group consisting of hydrogen and methyl
- R 5 is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl, C3-C10 heterocyclyl, C1-C3 haloalkyl and C3-C10 heterocyclyl substituted with halogen, -OH, -N3 ⁇ 4, C1-C6 alkyl and C1-C6 alkyl substituted with -OH or - NH 2 ;
- Z is any structure of the following group A;
- X 1 is, independently at each occurrence, selected from CR 24 and N;
- X 2 is, independently at each occurrence, selected from CR 25 and N;
- R 9 is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, -OR 5 , -CN, C3-C10 cycloalkyl, C3-C10 heterocyclyl and C1-C6 alkyl substituted with -OH or -OR 5 ;
- R 11 is, at each occurrence, independently selected from the group consisting of hydrogen, Cl- C6 alkyl and C3-C10 cycloalkyl;
- R 13 is, at each occurrence, independently selected from the group consisting of hydrogen, Cl- C6 alkyl, C1-C6 alkyl substituted with -CN, -OH, -OR 5 , -NH 2 , -NHR 5 or -N(R 5 )R 5 and C3- C10 cycloalkyl;
- R 17 , R 18 , R 19 and R 20 are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, C6-C10 aryl, e.g.
- R 21 is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 heterocyclyl, C1-C3 haloalkyl, aryl, phenyl, benzyl, C1-C6 alkyl substituted with -CN, -OH, -OR 5 , -NH 2 , -NHR 5 or -N(R 5 )R 5 , aryl substituted with halogen or C1-C3 haloalkyl, C3-C 10 heteroaryl substituted with one to four halogens or C1-C3 alkyl and C3-C10 heterocyclyl substituted with R 4 ;
- R 22 and R 23 are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, -OH, -OR 5 , -CN and C1-C6 alkyl substituted with -OH, -OR 5 or -NHR 9 ;
- R 24 and R 25 are, at each occurrence, independently selected from the group consisting of 7
- R 1 is H
- R 2 is CH(CH 3 ) 2
- R 3 is N3 ⁇ 4
- R 4 is H
- L 1 is absent
- Q is absent
- L 2 is absent
- X is N
- n is 1
- Y 1 is N
- Y 2 is CH
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 6 is not lH-pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- R 3 is CH 3
- R 4 is H
- L 1 is O
- Q is absent
- L 2 is absent
- X is N
- n is 1
- Y 1 is CH
- Y 2 is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H, then R 6 is not CH 3 , Cl or lH-pyrazole;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- R 3 is CH 3
- R 4 is H
- L 1 is O
- Q is absent
- L 2 is absent
- X is N
- n is 1
- Y 1 is CH
- Y 2 is N
- Z is phenyl
- R 6 is OR 12
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H, then R 12 is not phenyl, CH(CH 3 ) 2 , CH 2 CH 3 or CH 3 ;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- R 3 is CH 3
- R 4 is H
- L 1 is O
- Q is absent
- L 2 is absent
- X is N
- n is 1
- Y 1 is CH
- Y 2 is N
- Z is phenyl
- R 6 is Cl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is not Cl
- R 1 is H
- R 2 is CH(CH 3 ) 2
- R 3 is CH 3
- R 4 is H
- L 1 is O
- Q is absent
- L 2 is absent
- X is N
- n is 1
- Y 1 is CH
- Y 2 is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is Cl
- R 6 is not Cl
- R 1 is H
- R 2 is CH(CH 3 ) 2
- R 3 is C3 ⁇ 4
- R 4 is H
- L 1 is O
- Q is absent
- L 2 is absent
- X is N
- n is 1
- Y 1 is CH
- Y 2 is N
- Z is phenyl
- R 6 is Cl
- R 7 is H
- R 8 is H and R 9 is H
- R 10 is not CH 3
- R 1 is H
- R 2 is CH(CH 3 ) 2
- R 3 is CH 3
- R 4 is H
- L 1 is O
- Q is absent
- L 2 is absent
- X is N
- n is 1 is 1, Y 1 is CH
- Y 2 is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is Cl
- R 6 is not CH 3 ;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- R 3 is CH 3
- R 4 is H
- L 1 is O
- Q is absent
- L 2 is absent
- X is N
- n is 1
- Y 1 is CH
- Y 2 is N
- Z is phenyl
- R 6 is F
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is not F
- R 1 is H
- R 2 is CH(CH 3 ) 2
- R 3 is CH 3
- R 4 is H
- L 1 is O
- Q is absent
- L 2 is absent
- X is N
- n is 1
- Y 1 is CH
- Y 2 is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is F, then R 6 is not F;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- X is N
- L 1 is O
- Q is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- n is 1
- R 3 is C3 ⁇ 4
- R 4 is H
- Z is phenyl
- R 6 is OR 12
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H, then R 12 is not C3 ⁇ 4;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- X is N
- Q is absent
- L 2 is absent
- Y 1 is N
- Y 2 is N
- n is 1
- R 3 is H
- R 4 is H
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H, then R 6 is not lH-pyr azole;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- X is N
- Q is absent
- L 2 is absent
- Y 1 is N
- Y 2 is CH
- n is 1
- R 3 is N3 ⁇ 4
- R 4 is H
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 1 is H
- R 2 is CH(CH 3 ) 2
- X is N
- L 1 is O
- Q is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- n is 1
- R 3 is H
- R 4 is H
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 6 is not lH-pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- X is N
- L 1 is O
- Q is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- n is 1
- R 3 is H
- R 4 is H
- Z is phenyl
- R 6 is OR 12
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H, then R 12 is not CH(CH 3 ) 2
- R 1 is H
- R 2 is CH(CH 3 ) 2
- X is N
- L 1 is O
- Q is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- n is 0,
- R 3 is H
- R 4 is H
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H, then R 6 is not lH-pyr azole;
- R 1 is H
- R 2 is CH(CH 3 )
- X is N
- L 1 is O
- Q is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- n is 0,
- R 3 is H
- R 4 is H
- Z is phenyl
- R 6 is OR 12
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H, then R 12 is not CH(CH 3 ) 2 ;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- X is N
- L 1 is O
- Q is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- n is 0,
- R 3 is H
- R 4 is H
- Z is phenyl
- R 6 is OR 12
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H, then R 12 is not CH 3 ;
- R 1 is CH 3
- R 2 is CH(CH ) 2
- X is N
- L 1 is O
- Q is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- n is 1
- R 3 is H
- R 4 is H
- Z is phenyl
- R 6 is OR 12
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H, then R 12 is not CH 3 ;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- R 3 is N3 ⁇ 4
- R 4 is H
- L 1 is O
- Q is absent
- L 2 is absent
- X is N
- n is 1
- Y 1 is CH
- Y 2 is CH
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 6 is not lH-pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- R 3 is H
- R 4 is H
- L 1 is NH
- Q is absent
- L 2 is absent
- X is N
- n is 0,
- Y 1 is CH
- Y 2 is N
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H
- R 6 is not lH-pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- R 3 is N3 ⁇ 4
- R 4 is H
- L 1 is absent
- Q is absent
- L 2 is absent
- X is N
- n is 0,
- Y 1 is N
- Y 2 is CH
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H
- R 10 is H, then R 6 is not lH-pyrazole;
- R 1 is H
- R 2 is CH(CH 3 ) 2
- R 3 is N3 ⁇ 4
- R 4 is H
- L 1 is NH
- Q is absent
- L 2 is absent
- X is N
- n is 1
- Y 1 is CH
- Y 2 is CH
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H
- R 6 is not lH-pyrazole
- R 1 is H
- R 2 is CH(CH 3 ) 2
- R 3 is H
- R 4 is NH 2
- L 1 is absent
- Q is absent
- L 2 is absent
- X is N
- n is 1
- Y 2 is CH
- Z is phenyl
- R 7 is H
- R 8 is H
- R 9 is H and R 10 is H
- R 6 is not lH-pyrazole
- R 1 is CH 3
- R 2 is CH(CH3) 2
- X is N
- L 1 is O
- Q is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- n 1
- R 3 is H
- R 4 is H
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H
- R 10 is H, then R 12 is not CH 3 ;
- R 1 is C3 ⁇ 4, R 2 is CH(CH 3 ) 2 , X is N, L 1 is O, Q is absent, L 2 is absent, Y 1 is CH, Y 2 is N, n is 1, R 3 is CH 3 , R 4 is H, Z is phenyl, R 6 is H, R 8 is H, R 9 is H and R 10 is H, then R 7 is not Cl;
- R 1 is C3 ⁇ 4, R 2 is CH(CH 3 ) 2 , X is N, L 1 is O, Q is absent, L 2 is absent, Y 1 is CH, Y 2 is N, n is 1, R 3 is H, R 4 is H, Z is phenyl, R 6 is H, R 7 is OR 12 , R 8 is H, R 9 is H and R 10 is H, then R 12 is not CH 3 ;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- X is N
- L 1 is O
- Q is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is N
- n 1
- R 3 is NH 2
- R 4 is H
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H
- R 10 is H
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- X is N
- L 1 is O
- Q is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is CH
- n 1
- R 3 is NH 2
- R 4 is H
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H
- R 10 is H
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- X is N
- L 1 is absent
- Q is absent
- L 2 is absent
- Y 1 is N
- Y 2 is CH
- n 1
- R 3 is NH 2
- R 4 is H
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H
- R 10 is H
- R 1 is CH 3 , R 2 is CH(CH 3 ) 2 , X is N, L 1 is NH, Q is absent, L 2 is absent, Y 1 is CH, Y 2 is N, n is 0, R 3 is H, R 4 is H, Z is phenyl, R 6 is H, R 7 is OR 12 , R 8 is H, R 9 is H and R 10 is H, then R 12 is not CH 3 ;
- R 1 is CH 3 , R 2 is CH(CH 3 )2
- X is N, L 1 is absent, Q is absent, L 2 is absent, Y 1 is N, Y 2 is CH, n is 0, R 3 is N3 ⁇ 4, R 4 is H, Z is phenyl, R 6 is H, R 7 is OR 12 , R 8 is H, R 9 is H and R 10 is H, then R 12 is not CH 3 ;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- X is N
- L 1 is NH
- Q is absent
- L 2 is absent
- Y 1 is CH
- Y 2 is CH
- n 1
- R 3 is N3 ⁇ 4
- R 4 is H
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H
- R 10 is H, then R 12 is not CH 3 ;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- X is N
- Q is absent
- L 2 is absent
- Y 1 is N
- Y 2 is N
- n 1
- R 3 is H
- R 4 is H
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H
- R 10 is H, then R 12 is not CH 3 ;
- R 1 is CH 3
- R 2 is CH(CH 3 ) 2
- X is N
- L 1 is absent
- Q is absent
- L 2 is absent
- Y 1 is N
- Y 2 is CH
- n 1
- R 3 is NH
- R 4 is N3 ⁇ 4
- Z is phenyl
- R 6 is H
- R 7 is OR 12
- R 8 is H
- R 9 is H
- R 10 is H, then R 12 is not CH 3 ;
- the present invention relates to compounds having the general formula IY
- Z 1 is any structure of the following group D;
- R 6 , R 7 , R 8 , R 9 and R 10 are as defined above for general formula I.
- the present invention relates to compounds having the general formula V
- the present invention relates to compounds having the general formula VI
- X 3 is, independently at each occurrence, selected from CR 10 and N;
- R , R and R are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, -OR 5 , -CN and C1-C6 alkyl substituted with -OH, -OR 5 or -NHR 9 ;
- R s , R 9 and R 10 are as defined above for general formula I;
- R 7 is any structure of the following group E;
- R 8 and R 14 - R 20 are as defined above for general formula I.
- the present invention relates to compounds having the general formula VII
- the present invention relates to compounds having the general formula VIII
- the present invention relates to compounds having the general formula IX
- Q 2 is any structure of the following group F;
- the present invention also relates to pharmaceutically acceptable salts of the compounds according to the present invention, as defined herein.
- the compound according to the present invention is a compound selected from structures 1 - 279, as listed further below in table 11.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound according to the present invention as defined herein, as an active ingredient, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.
- the present invention also relates to a compound according to the present invention as defined herein, for use as a pharmaceutical or pharmaceutically active agent, wherein said pharmaceutical or pharmaceutically active agent preferably has an inhibitory activity on cyclin-dependent kinase 7 (CDK7).
- CDK7 cyclin-dependent kinase 7
- the present invention also relates to a compound according to the present invention, as defined herein, for use in a method of prevention and/or treatment of a disease which is associated with inhibition of apoptosis, abnormal transcriptional activity and/or cell cycle arrest by aberrant activity and/or overexpression of one or several cyclin-dependent kinases (CDKs), in particular cyclin-dependent kinase 7 (CDK7), wherein the disease is selected from proliferative diseases, infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, and inflammatory diseases.
- CDKs cyclin-dependent kinases
- CDK7 cyclin-dependent kinase 7
- the disease associated with inhibition of apoptosis, abnormal transcriptional activity and/or cell cycle arrest by aberrant activity and/or overexpression of one or several cyclin-dependent kinases (CDKs), in particular cyclin-dependent kinase 7 (CDK7) is a disease associated with, accompanied by, caused by and/or induced by CDK7 dysfunction and/or hyperfunction.
- the disease associated with inhibition of apoptosis, abnormal transcriptional activity and/or cell cycle arrest by aberrant activity and/or overexpression of one or several cyclin-dependent kinases (CDKs), in particular cyclin-dependent kinase 7 (CDK7) is a proliferative disease.
- said proliferative disease is a cancer.
- said cancer is selected from adenocarcinoma, choroidal melanoma, acute leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma, pancreatic cancer, Desmoid tumor, bladder cancer, bronchial carcinoma, estrogen dependent and independent breast cancer, Burldtt’s lymphoma, corpus cancer, Carcinoma unknown primary tumor (CUP-syndrome), colorectal cancer, small intestine cancer, small intestinal tumors, ovarian cancer, endometrial carcinoma, ependymoma, epithelial cancer types, Ewing’s tumors, gastrointestinal tumors, gastric cancer, gallbladder cancer, gall bladder carcinomas, uterine cancer, cervical cancer, cervix, glioblastomas, gynecologic tumors, ear, nose and throat tumors, hematologic tumor, hairy cell leukemia, urethral cancer, skin cancer
- said infectious disease including opportunistic diseases, is selected from AIDS, Adenovirus Infection, Alveolar Hydatid Disease (AHD), Amoebiasis, Angiostrongyliasis, Anisakiasis, Anthrax, Babesiosis, Balantidiasis, Baylisascaris Infection, Bilharzia (Schistosomiasis), Blastocystis hominis Infection, Lyme Borreliosis, Botulism, Brainerd Diarrhea, Brucellosis, Bovine Spongiform Encephalopathy (BSE), Candidiasis, Capillariasis, Chronic Fatigue Syndrome (CFS), Chagas Disease, Chickenpox, Chlamydia pneumoniae Infection, Cholera, Chronic Fatigue Syndrome, Creutzfeldt- Jakob Disease (CJD), Clonorchiasis, Cutaneous Larva migrans (CLM), Coccidioidomycosis
- the immunological disease and/or autoimmune disease is selected from asthma, diabetes, rheumatic diseases, rejection of transplanted organs and tissues, rhinitis, chronic obstructive pulmonary diseases, osteoporosis, ulcerative colitis, sinusitis, lupus erythematosus, recurrent infections, atopic dermatitis / eczema and occupational allergies, food allergies, drug allergies, severe anaphylactic reactions, anaphylaxis, manifestations of allergic diseases, primary immunodeficiencies, antibody deficiency states, cell mediated immunodeficiencies, severe combined immunodeficiency, DiGeorge syndrome, Hyper IgE syndrome (HIES), Wiskott-Aldrich syndrome (WAS), ataxia-telangiectasia, immune mediated cancers, white cell defects, autoimmune diseases, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), immune-mediated or Type
- the inflammatory disease is caused, induced, initiated and/or enhanced by bacteria, viruses, prions, parasites, fungi, and/or caused by irritative, traumatic, metabolic, allergic, autoimmune, or idiopathic agents.
- the inflammatory disease is selected from the group comprising or consisting of inflammatory diseases of the central nervous system (CNS), inflammatory rheumatic diseases, inflammatory diseases of blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory diseases of the skin, inflammatory disease uveitis, and inflammatory diseases of the larynx.
- CNS central nervous system
- inflammatory rheumatic diseases inflammatory diseases of blood vessels
- inflammatory diseases of the middle ear inflammatory diseases of the middle ear
- inflammatory bowel diseases inflammatory diseases of the skin
- inflammatory disease uveitis inflammatory diseases of the larynx.
- the inflammatory disease is selected from inflammatory diseases of the central nervous system (CNS), inflammatory rheumatic diseases, inflammatory diseases of blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory diseases of the skin, inflammatory disease uveitis, inflammatory diseases of the larynx, wherein preferably said inflammatory diseases are selected from the group comprising abscessation, acanthamoeba infection, acne vulgaris, actinomycosis, acute inflammatory dermatoses, acute laryngeal infections of adults, acute multifocal placoid pigment epitheliopathy, acute (thermal) injury, acute retinal necrosis, acute suppurative otitis media, algal disorders, allergic contact dermatitis, amyloidosis angioedema, ankylosing spondylitis, aspergillosis, atopic dermatitis, pseudorabies, autoantibodies in vasculitis, bacterial disorders, bacterial laryngit
- the present invention also relates to a method of treatment and/or prevention of a disease which is associated with inhibition of apoptosis, abnormal transcriptional activity and/or cell cycle arrest by aberrant activity and/or overexpression of one or several cyclin-dependent kinases (CDKs), in particular cyclin-dependent kinase 7 (CDK7), wherein the disease is selected from proliferative diseases, infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, and inflammatory diseases, wherein said method of treatment and/or prevention comprises administering a compound according to the present invention as defined herein, to a patient in need thereof.
- CDKs cyclin-dependent kinases
- CDK7 cyclin-dependent kinase 7
- the patient in need thereof is a mammal. In one embodiment, the patient in need thereof is a human being. In another embodiment, the patient in need thereof is a nonhuman animal.
- the disease which is prevented or treated in said method is as defined herein.
- the present invention also relates to the use of a compound according to the present invention as defined herein in the manufacture of a medicament for the prevention and/or treatment of a disease which is associated with inhibition of apoptosis, abnormal transcriptional activity and/or cell cycle arrest by aberrant activity and/or overexpression of one or several cyclin-dependent kinases (CDKs), in particular cyclin-dependent kinase 7 (CDK7), wherein the disease is selected from proliferative diseases, infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, and inflammatory diseases, as defined herein.
- CDKs cyclin-dependent kinases
- CDK7 cyclin-dependent kinase 7
- the compounds of the present invention are highly efficient inhibitors of CDK7 threonine/serine kinase and/or its complex, CDK7/MATl/CycH.
- the inventive compounds are suitable for the use as a pharmaceutically active agent.
- the inventive compounds are suitable for the treatment of disorders associated with, accompanied by, caused by and/or induced by CDK7 and its complex, in particular a hyperfunction or dysfunction thereof.
- the inventive compounds are thus suitable for the treatment of CDK7-associated diseases or disorders and CDK7 complex induced disorders.
- inventive compounds are also useful in the manufacture of a medicament or of a pharmaceutical composition for the treatment of disorders associated with, accompanied by, caused by and/or induced by CDK7 and its complex, in particular a hyperfunction or dysfunction thereof.
- inventive compounds are further used in the manufacture of a medicament or of a pharmaceutical composition for the treatment and/or prevention of CDK7 and its complex induced disorders.
- halogen including fluorine, C ! -C 3 alkyl, C1-C3 haloalkyl, methylhydroxyl, COOMe, C(0)H, COOH, OMe, or OCF 3 ;
- alkyl refers to a monovalent straight, branched or cyclic chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range.
- “C C 6 alkyl” refers to any of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec-, and t-butyl, n- and isopropyl, cyclic propyl, ethyl and methyl.
- alkenyl refers to a monovalent straight or branched chain aliphatic hydrocarbon radical containing one carbon-carbon double bond and having a number of carbon atoms in the specified range.
- “C 2 -C 6 alkenyl” refers to all of the hexenyl and pentenyl isomers as well as 1-butenyl, 2-butenyl, 3-butenyl, isobutenyl, l-propenyl, 2- propenyl, and ethenyl (or vinyl).
- cycloalkyl refers to a group, such as optionally substituted or non-substituted cyclic hydrocarbon, having from three to eight carbon atoms, unless otherwise defined.
- “C 3 -Cs cycloalkyl” refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- haloalkyl refers to an alkyl group, as defined herein that is substituted with at least one halogen.
- straight or branched chained“haloalkyl” groups useful in the present invention include, but are not limited to, methyl, ethyl, propyl, isopropyl, «-butyl, and /-butyl substituted independently with one or more halogens.
- the term“haloalkyl” should be interpreted to include such substituents such as -CHF 2 , -CF 3 , -CH 2 -CH 2 -F, -CH 2 -CF 3 , and the like.
- heteroalkyl refers to an alkyl group where one or more carbon atoms have been replaced with a heteroatom, such as, O, N, or S.
- a heteroatom e.g., O, N, or S
- the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g., -OCTl 3 , etc.), an amine (e.g, -NFICH 3 , -N(CH 3 ) 2 , etc.), or thioalkyl group (e.g., -SC3 ⁇ 4, etc.).
- a non-terminal carbon atom of the alkyl group which is not attached to the parent molecule is replaced with a heteroatom (e.g., O, N, or S) and the resulting heteroalkyl groups are, respectively, an alkyl ether (e.g., -CH CH 2 -0-CH 3 , etc.), alkyl amine (e.g., -CH 2 NHCF1 3 , -CFI 2 N(CH3) 2 , etc.), or thioalkyl ether (e.g., -CH 2 -S-CH 3 ).
- an alkyl ether e.g., -CH CH 2 -0-CH 3 , etc.
- alkyl amine e.g., -CH 2 NHCF1 3 , -CFI 2 N(CH3) 2 , etc.
- thioalkyl ether e.g., -CH 2 -S-CH 3
- halogen refers to fluorine, chlorine, bromine, or iodine.
- phenyl as used herein is meant to indicate that optionally substituted or non- substituted phenyl group.
- heteroaryl refers to (i) optionally substituted 5- and 6-membered heteroaromatic rings and (ii) optionally substituted 9- and 10-membered bicyclic, fused ring systems in which at least one ring is aromatic, wherein the heteroaromatic ring or the bicyclic, fused ring system contains from 1 to 4 heteroatoms independently selected from N, O, and S, where each N is optionally in the form of an oxide and each S in a ring which is not aromatic is optionally S(O) or S(0) 2 .
- Suitable 5- and 6-membered heteroaromatic rings include, for example, pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl.
- Suitable 9-and lO-membered heterobicyclic, fused ring systems include, for example, benzofuranyl, indolyl, indazolyl, naphthyridinyl, isobenzofuranyl, benzopiperidinyl, benzisoxazolyl, benzoxazolyl, chromenyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, isoindolyl, benzodioxolyl, benzofuranyl, imidazo[l,2-a]pyridinyl, benzotriazolyl, dihydroindolyl, dihydroisoindolyl, indazolyl, indolinyl, isoindolinyl, quinoxalinyl, quinazolinyl, 2,3- dihydr
- heterocyclyl refers to (i) optionally substituted 4- to 8-membered, saturated and unsaturated but non-aromatic monocyclic rings containing at least one carbon atom and from 1 to 4 heteroatoms, (ii) optionally substituted bicyclic ring systems containing from 1 to 6 heteroatoms, and (iii) optionally substituted tricyclic ring systems, wherein each ring in (ii) or (iii) is independent of fused to, or bridged with the other ring or rings and each ring is saturated or unsaturated but nonaromatic, and wherein each heteroatom in (i), (ii), and (iii) is independently selected from N, O, and S, wherein each N is optionally in the form of an oxide and each S is optionally oxidized to S(O) or S(0) 2 .
- Suitable 4- to 8-membered saturated heterocyclyls include, for example, azetidinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, pyrrolidinyl, imidazolidinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, hexahydropyrimidinyl, thiazinanyl, thiazepanyl, azepanyl, diazepanyl, tetrahydropyranyl, tetrahydrothiopyranyl, dioxanyl, and azacyclooctyl.
- Suitable unsaturated heterocyclic rings include those corresponding to the saturated heterocyclic rings listed in the above sentence in which a single bond is replaced with a double bond. It is understood that the specific rings and ring systems suitable for use in the present invention are not limited to those listed in this and the preceding paragraphs. These rings and ring systems are merely representative.
- Examples of pharmaceutically acceptable addition salts include, without limitation, the nontoxic inorganic and organic acid addition salts such as the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulfonate derived from benzensulfonic acid, the benzoate derived from benzoic acid, the cinnamate derived from cinnamic acid, the citrate derived from citric acid, the embonate derived from embonic acid, the enantate derived from enanthic acid, the formate derived from formic acid, the fumarate derived from fumaric acid, the glutamate derived from glutamic acid, the glycolate derived from glycolic acid, the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the lactate derived from lactic acid, the maleate derived from maleic acid, the malonate derived from malonic
- acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt.
- the compounds of the invention are used in their respective free base form according to the present invention.
- Metal salts of a chemical compound of the invention include alkali metal salts, such as the sodium salt of a chemical compound of the invention containing a carboxy group.
- the chemical compounds of the invention may be provided in unsolvated or solvated forms together with a pharmaceutically acceptable solvent(s) such as water, ethanol, and the like.
- Solvated forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, solvated forms are considered equivalent to unsolvated forms for the purposes of this invention.
- Table 10 shows comparative data of a panel assay showing the CDK7 selectivity profile in CDKs family for compound 210 of the invention.
- Table 11 summarizes compounds 1-279 in terms of their structures and corresponding characteristics.
- Figure 1 show in vivo antitumor activity of CDK7 inhibitor in OVCAR-3 xenograft model.
- Example 1 Enzymatic assay for CDKL CDK2, CDK5 and CDK7
- CDKl/Cyclin B Invitrogen, Cat# PR4768C
- 22 uM for CDK2/Cyclin A Invitrogen, Cat# PV6290
- 10 uM for CDK5/p25 Invitrogen, Cat# PR8543B
- 400 uM for CDK7/Cyclin H/MNAT1 Invitrogen, Cat# PR6749B
- Example 2 Cellular HCT116. H460, MV4-11. MM.1S. MOLT-4. RPMI-8226. A2780 and OVCAR-3 viability assay
- Cells were grown in RPMI-1640 media (Invitrogen, Cat#22400-089) supplemented with 10% FBS (Invitrogen, Cat# 10099141) and 1% penicillin/streptomycin (Invitrogen, Cat# 15070063) and cultured at 37 ° C , 5%C0 2 in a humidified chamber. All cell lines were routinely tested for mycoplasma.
- Cell HCT116, H460, MV4-11, MM.1S, MOLT-4, RPMI-8226, A2780 and OVCAR-3 viability assay protocol The effect of the CDK7 inhibitor to inhibit the growth of target cancer cells was evaluated through the 72 hours time period of viability assay. Briefly, the candidate cell line ware plated in 96 well plate at the following density of cells respectively. 1 X 10 4 cells/well for MOLT-4, RPMI-8226, MV4-11 and MM.1S, 5 X 10 3 for H460, HCT116 and OVCAR-3 and IX l0 3 for A2780. After 24 hours, the cells were treated with various concentrations of the compound (ranging from 0.0015uM to lOuM).
- DMSO solvent without compound served as a control and final DMSO concentration lest than 0.1%.
- DMSO concentration lest than 0.1%.
- cells were analyzed for the viability using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Cat# G7570). All viability assays were performed in duplicate and Luminescence was read using an Envision (Perkin Elmer, USA). Data was analyzed using XLfit software.
- the IC50 profile of compounds were determined using 28 CDKs family protein kinases through ProQinase GmbH (Freiburg, Germany). All the protocol and materials had been provided by ProQinase GmbH. Briefly, in the process, 90 m ⁇ H 2 0 were added to each well of a compound dilution plate. To minimize potential precipitation, the H 2 0 was added to the plate only a few minutes before the transfer of the compound solutions into the assay plates. The plate was shaken thoroughly, resulting in a "compound dilution plate/ 10 % DMSO". The compound dilution plate(s) were discarded at the end of the working day.
- the purity of the protein kinases was examined by SDS-PAGE/Coomassie staining, the identity was checked by mass spectroscopy.
- Kinases from external vendors, Cama Biosciences Inc.; Invitrogen Corp.; and Millipore Corp. were expressed, purified and quality-controlled by virtue of the vendors readings.
- a radiometric protein kinase assay 33 PanQinase ® Activity Assay was used for measuring the kinase activity of the 28 protein kinases. All kinase assays were performed in 96-well FlashPlatesTM from PerkinElmer (Boston, MA, USA) in a 50 m ⁇ reaction volume. The reaction cocktails were incubated at 30 °C for 60 minutes. The reaction was stopped with 50 m ⁇ of 2 % (v/v)
- OVCAR-3 (ATCC, HTB-161) xenograft tumors
- OVCAR-3 cells were grown in RPMI-1 640 medium (Gibco, C2400500BT) supplemented with 20 % fetal bovine serum(HyCl one, SV30087.03), 0.01 mg/ml bovine insulin (Yuanyue, S12033) and 1 % anti anti(G ibco, 15240-062) at 37 ° C in an atmosphere of 5 % C0 2 in air.
- Route II Route II having the similar reaction condition with Route I and different order.
- Compound Cl 3 can be synthesized by treating in presence of m-CPBA.
- the compounds of formula II- 1 can be synthesized by treating compounds C13 with appropriated group A.
- Compounds II-2 can be synthesized by treating in presence of POCl 3 .
- the compounds of formula 1-3 can be synthesized by treating compounds II-2 with DIPEA and group B.
- the compounds of formula 1-4 can be prepared by using compounds of formula 1-3 in presence of acid such as TFA, HBr and AcOH, or base such as hydrazine.
- Compound El can be synthesized by treating in presence of NaOEt.
- Compound E2 can be synthesized by treating in presence of POCl 3 .
- Compound E2 can be further treated with group B in presence of K 2 C0 3 to give compounds III- 1.
- Compounds III-1 can be further treated with group A to provide the compounds of formula III-2.
- the compounds of formula III-3 can be prepared by using compounds of formula III-2 in presence of acid such as TFA, HBr and AcOH, or base such as hydrazine. Procedure for synthesis of El
- reagent for group A such as tert-butyl piperidin-3- ylcarbamate, tert-butyl 4-aminopiperidine-l-carboxylate, piperidine-4-carboxamide, tert- butyl (4-methylpiperidin-4-yl)carbamate, tert-butyl piperidin-4-ylcarbamate, benzyl piperidin-4-ylcarbamate, piperidin-4-ol, piperazine, piperazin-2-one, tetrahydro-2H-pyran-4- amine, tert-butyl 3-methylpiperazine-l-carboxylate, N-(piperidin-4-yl)acetamide, 1- methylpiperidin-4-ol, tert-butyl ((4-hydroxypiperidin-4-yl)methyl)carbamate, tert-butyl (morpholin-2-ylmethyl)carbamate, tert-butyl 4-(amino
- reaction mixture was quenched with NH 4 C1 (200 mL) and extracted with EA (150 mL x 2). The organic layer was dried over anhydrous Na 2 S0 4 , filtered and concentrated under reduced pressure to give crude product. The residue was purified by column chromatography to give compound B124 (1.3 g) as light yellow oil.
- the compound B140 (500 mg) was followed the same procedure of B26 to obtain 910 mg of compound B141 as a yellow powder.
- the compound B142 (100 mg) was followed the same procedure of B28 to obtain 100 mg of compound B 143 as a pale-yellow powder.
- the red solid was purified by cation exchange resin eluting with 5% NH 3 .H 2 0, then lyophilized to give a white powder, which was purified by prep-TLC and lyophilized to give compound 178 (20.5 mg) as a white powder.
- N- isopropylpropan-2-amine (13.7 g, 135 mmol) dropwise at -70 °C under N 2 atmosphere.
- the mixture was stirred at 15 °C for 1 hour under N 2 atmosphere.
- compound D9 (12.0 g, 123 mmol) in anhydrous THF (20 mL) was added into the mixture at -70 °C under N 2 atmosphere and the resulting mixture was stirred at -70 °C under N 2 atmosphere for 2 hours.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201980039582.5A CN112313235A (en) | 2018-04-11 | 2019-04-11 | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitors of cyclin dependent kinases |
IL277770A IL277770B2 (en) | 2018-04-11 | 2019-04-11 | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
CA3095880A CA3095880A1 (en) | 2018-04-11 | 2019-04-11 | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
US17/045,030 US11945822B2 (en) | 2018-04-11 | 2019-04-11 | Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase |
AU2019250507A AU2019250507B2 (en) | 2018-04-11 | 2019-04-11 | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
EP19720425.8A EP3774810A1 (en) | 2018-04-11 | 2019-04-11 | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
BR112020020768-3A BR112020020768A2 (en) | 2018-04-11 | 2019-04-11 | PIRAZOL-TRIAZINE DERIVATIVES AND / OR PIRAZOL-PYRIMIDINE AS A SELECTIVE CYCLINE-DEPENDENT KINASE INHIBITOR |
JP2020555100A JP2021521120A (en) | 2018-04-11 | 2019-04-11 | Pyrazolo-triazine derivatives and / or pyrazolo-pyrimidine derivatives as selective inhibitors of cyclin-dependent kinases |
KR1020207032379A KR20200141487A (en) | 2018-04-11 | 2019-04-11 | Pyrazolo-triazine and/or pyrazolopyrimidine derivatives as selective inhibitors of cyclin dependent kinases |
SG11202009724YA SG11202009724YA (en) | 2018-04-11 | 2019-04-11 | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
MX2020010675A MX2020010675A (en) | 2018-04-11 | 2019-04-11 | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase. |
PH12020551639A PH12020551639A1 (en) | 2018-04-11 | 2020-10-05 | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
JP2023131904A JP2023138858A (en) | 2018-04-11 | 2023-08-14 | Pyrazolo-triazine derivatives and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862656070P | 2018-04-11 | 2018-04-11 | |
US62/656,070 | 2018-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019197549A1 true WO2019197549A1 (en) | 2019-10-17 |
Family
ID=66334385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2019/059302 WO2019197549A1 (en) | 2018-04-11 | 2019-04-11 | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
Country Status (13)
Country | Link |
---|---|
US (1) | US11945822B2 (en) |
EP (1) | EP3774810A1 (en) |
JP (2) | JP2021521120A (en) |
KR (1) | KR20200141487A (en) |
CN (1) | CN112313235A (en) |
AU (1) | AU2019250507B2 (en) |
BR (1) | BR112020020768A2 (en) |
CA (1) | CA3095880A1 (en) |
IL (1) | IL277770B2 (en) |
MX (1) | MX2020010675A (en) |
PH (1) | PH12020551639A1 (en) |
SG (1) | SG11202009724YA (en) |
WO (1) | WO2019197549A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020186196A1 (en) * | 2019-03-13 | 2020-09-17 | The Translational Genomics Research Institute | Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors |
CN112079781A (en) * | 2020-09-30 | 2020-12-15 | 苏州康润医药有限公司 | Synthesis method of 5-bromo-1-methyl-1H-pyrazol-3-amine |
WO2021116178A1 (en) * | 2019-12-11 | 2021-06-17 | Bayer Aktiengesellschaft | Pyrazolotriazines |
WO2021121390A1 (en) | 2019-12-20 | 2021-06-24 | 苏州信诺维医药科技股份有限公司 | Heterocyclic compound, and pharmaceutical composition thereof, preparation method therefor, intermediate thereof and application thereof |
WO2021122745A1 (en) | 2019-12-16 | 2021-06-24 | Carrick Therapeutics Limited | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds and their therapeutic use |
WO2022117504A1 (en) * | 2020-12-02 | 2022-06-09 | Qurient Co., Ltd. | Compounds having cyclin-dependent kinase(cdk)-inhibitory function |
CN115485030A (en) * | 2020-03-06 | 2022-12-16 | 拜耳公司 | Imidazotriazines acting on cancer through inhibition of CDK12 |
WO2022263604A1 (en) * | 2021-06-16 | 2022-12-22 | Carrick Therapeutics Limited | Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114195710A (en) * | 2021-12-20 | 2022-03-18 | 上海彩迩文生化科技有限公司 | Preparation method of quinoline aminomethyl compound |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US615968A (en) | 1898-12-13 | Apparatus for treating ores | ||
WO2013128029A1 (en) * | 2012-03-01 | 2013-09-06 | Lead Discovery Center Gmbh | Pharmaceutically active pyrazolo-triazine derivatives |
WO2013128028A1 (en) | 2012-03-01 | 2013-09-06 | Lead Discovery Center Gmbh | Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhinitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8673924B2 (en) * | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
JP2009007342A (en) * | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | Medicinal composition |
GB201403093D0 (en) * | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
AU2015240518A1 (en) | 2014-04-05 | 2016-10-20 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
JP6789962B2 (en) | 2015-03-09 | 2020-11-25 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | Pyrazolo [1,5-a] [1,3,5] triazine and pyrazolo [1,5-a] pyrimidine derivatives as CDK inhibitors |
WO2019144149A2 (en) * | 2018-01-22 | 2019-07-25 | Fred Hutchinson Cancer Research Center | Treatment methods for pancreatic tumors associated with the worst prognosis |
-
2019
- 2019-04-11 EP EP19720425.8A patent/EP3774810A1/en active Pending
- 2019-04-11 US US17/045,030 patent/US11945822B2/en active Active
- 2019-04-11 KR KR1020207032379A patent/KR20200141487A/en unknown
- 2019-04-11 JP JP2020555100A patent/JP2021521120A/en active Pending
- 2019-04-11 AU AU2019250507A patent/AU2019250507B2/en active Active
- 2019-04-11 CN CN201980039582.5A patent/CN112313235A/en active Pending
- 2019-04-11 SG SG11202009724YA patent/SG11202009724YA/en unknown
- 2019-04-11 CA CA3095880A patent/CA3095880A1/en active Pending
- 2019-04-11 MX MX2020010675A patent/MX2020010675A/en unknown
- 2019-04-11 WO PCT/EP2019/059302 patent/WO2019197549A1/en active Application Filing
- 2019-04-11 BR BR112020020768-3A patent/BR112020020768A2/en unknown
- 2019-04-11 IL IL277770A patent/IL277770B2/en unknown
-
2020
- 2020-10-05 PH PH12020551639A patent/PH12020551639A1/en unknown
-
2023
- 2023-08-14 JP JP2023131904A patent/JP2023138858A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US615968A (en) | 1898-12-13 | Apparatus for treating ores | ||
WO2013128029A1 (en) * | 2012-03-01 | 2013-09-06 | Lead Discovery Center Gmbh | Pharmaceutically active pyrazolo-triazine derivatives |
WO2013128028A1 (en) | 2012-03-01 | 2013-09-06 | Lead Discovery Center Gmbh | Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhinitors |
Non-Patent Citations (22)
Title |
---|
A. J. KAPASI; D. H. SPECTOR: "Inhibition of the Cyclin-Dependent Kinases at the Beginning of Human Cytomegalovirus Infection Specifically Alters the Levels and Localization of the RNA Polymerase II Carboxyl-Terminal Domain Kinases cdk9 and cdk7 at the Viral Transcriptosome", J. VIROL., vol. 82, no. 1, January 2008 (2008-01-01), pages 394 - 407 |
AKHTAR ET AL., MOL. CELL, vol. 34, 2009, pages 387 - 393 |
BREGMAN ET AL., FRONT BIOSCI., vol. 5, 2000, pages 244 - 257 |
CORINA HUTTERER ET AL: "A Novel CDK7 Inhibitor of the Pyrazolotriazine Class Exerts Broad-Spectrum Antiviral Activity at Nanomolar Concentrations", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 59, no. 4, 1 April 2015 (2015-04-01), US, pages 2062 - 2071, XP055593407, ISSN: 0066-4804, DOI: 10.1128/AAC.04534-14 * |
D. B. BREGMAN; R.G. PESTELL; V. J. KIDD: "Cell cycle regulation and RNA polymerase II", FRONT BIOSCI., vol. 1, no. 5, February 2000 (2000-02-01), pages D244 - 57 |
D. DESAI; H. C. WESSLING; R. P. FISHER; D. O. MORGAN: "Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2", MOL. CELL BIOL., vol. 15, no. 1, January 1995 (1995-01-01), pages 345 - 350, XP002405789 |
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 14 June 2012 (2012-06-14), XP002793432, Database accession no. 1378219-23-8 * |
DESAI ET AL., MOL. CELL BIOL., vol. 15, 1995, pages 345 - 350 |
G. I. SHAPIRO: "Cyclin-Dependent Kinase Pathways as Targets for Cancer Treatment", J. CLIN. ONCOL., vol. 24, no. 11, April 2006 (2006-04-01), pages 1770 - 83, XP009148872, DOI: doi:10.1200/JCO.2005.03.7689 |
G. LOLLI; L. N. JOHNSON: "CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?", CELL CYCLE, vol. 4, no. 4, April 2005 (2005-04-01), pages 572 - 7 |
LAROCHELLE ET AL., NAT. STRUT. MOL. BIOL., vol. 19, 2012, pages 1108 - 1115 |
LOLLI G; JOHNSON LN, CELL CYCLE, vol. 4, 2005, pages 572 - 577 |
NEKHAI ET AL., BIOCHEM J., vol. 364, 2002, pages 649 - 657 |
S. AKHTAR; M. HEIDEMANN; J. R. TIETJEN; D. W. ZHANG; R. D. CHAPMAN; D. EICK; A. Z. ANSARI: "TFIIH Kinase Places Bivalent Marks on the Carboxy-Terminal Domain of RNA Polymerase II", MOL. CELL., vol. 34, no. 3, May 2009 (2009-05-01), pages 387 - 93 |
S. LAROCHELLE; R. AMAT; K. G. CUTTER; M. SANSO; C. ZHANG; J. J. ALLEN; K. M. SHOKAT; D. L. BENTLEY; R. P. FISHER: "Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II", NAT. STRUCT. MOL. BIOL., vol. 19, no. 11, November 2012 (2012-11-01), pages 1108 - 15 |
S. NEKHAI; M. ZHOU; A. FERNANDEZ; W. S. LANE; NED J.C. LAMB; J. BRADY; A. KUMAR, BIOCHEM. J., vol. 364, June 2002 (2002-06-01), pages 649 - 57 |
SHAPIRO GI., J CLIN ONCOL, vol. 24, no. 11, 2006, pages 1770 - 83 |
T. I. LEE; R. A. YOUNG: "Transcriptional Regulation and its misregulation in Disease", CELL, vol. 152, no. 6, March 2013 (2013-03-01), pages 1237 - 51, XP029001372, DOI: doi:10.1016/j.cell.2013.02.014 |
TAMRAKAR ET AL., JOURNAL OF VIROLOGY, vol. 79, 2005, pages 15477 - 15493 |
TONG IHN LEE; RICHARD A. YOUNG, CELL, vol. 152, 2013, pages 1237 - 1251 |
Y. K. KIM; C. F. BOURGEOIS; R. PEARSON; M. TYAGI; M. J. WEST; J. WONG; S. Y. WU; C. M. CHIANG; J. KARN: "Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency", EMBO. J., vol. 25, no. 15, August 2006 (2006-08-01), pages 3596 - 3604 |
YOUNG KYEUNG KIM, EMBO, vol. 25, 2006, pages 3596 - 3604 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020186196A1 (en) * | 2019-03-13 | 2020-09-17 | The Translational Genomics Research Institute | Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors |
WO2021116178A1 (en) * | 2019-12-11 | 2021-06-17 | Bayer Aktiengesellschaft | Pyrazolotriazines |
CN115023427A (en) * | 2019-12-11 | 2022-09-06 | 拜耳公司 | Pyrazolotriazines |
WO2021122745A1 (en) | 2019-12-16 | 2021-06-24 | Carrick Therapeutics Limited | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds and their therapeutic use |
WO2021121390A1 (en) | 2019-12-20 | 2021-06-24 | 苏州信诺维医药科技股份有限公司 | Heterocyclic compound, and pharmaceutical composition thereof, preparation method therefor, intermediate thereof and application thereof |
CN115485030A (en) * | 2020-03-06 | 2022-12-16 | 拜耳公司 | Imidazotriazines acting on cancer through inhibition of CDK12 |
CN112079781A (en) * | 2020-09-30 | 2020-12-15 | 苏州康润医药有限公司 | Synthesis method of 5-bromo-1-methyl-1H-pyrazol-3-amine |
CN112079781B (en) * | 2020-09-30 | 2022-11-22 | 苏州康润医药有限公司 | Synthesis method of 5-bromo-1-methyl-1H-pyrazol-3-amine |
WO2022117504A1 (en) * | 2020-12-02 | 2022-06-09 | Qurient Co., Ltd. | Compounds having cyclin-dependent kinase(cdk)-inhibitory function |
WO2022263604A1 (en) * | 2021-06-16 | 2022-12-22 | Carrick Therapeutics Limited | Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use |
Also Published As
Publication number | Publication date |
---|---|
CA3095880A1 (en) | 2019-10-17 |
JP2021521120A (en) | 2021-08-26 |
US11945822B2 (en) | 2024-04-02 |
AU2019250507A1 (en) | 2020-10-22 |
AU2019250507B2 (en) | 2023-09-28 |
IL277770B1 (en) | 2023-09-01 |
SG11202009724YA (en) | 2020-10-29 |
US20210147427A1 (en) | 2021-05-20 |
BR112020020768A2 (en) | 2021-01-19 |
EP3774810A1 (en) | 2021-02-17 |
JP2023138858A (en) | 2023-10-02 |
PH12020551639A1 (en) | 2021-07-05 |
IL277770A (en) | 2020-11-30 |
CN112313235A (en) | 2021-02-02 |
MX2020010675A (en) | 2020-10-28 |
IL277770B2 (en) | 2024-01-01 |
KR20200141487A (en) | 2020-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019250507B2 (en) | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase | |
AU2019250504B2 (en) | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives | |
CN108368089B (en) | Deubiquitinase inhibitor | |
JP6666263B2 (en) | A novel inhibitor of glutaminase | |
JP5833010B2 (en) | Pyrazolopyridine derivatives as anticancer agents | |
CN110997677A (en) | Btk inhibitors with improved dual selectivity | |
JPWO2007126128A1 (en) | Dihydropyrazolopyrimidinone derivatives | |
CZ304344B6 (en) | Quinolinone derivatives and their use as well as pharmaceutical compositions in which the derivatives are comprised | |
MX2012010344A (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors. | |
JP2007217427A (en) | Aza heterocyclic derivative and its therapeutic use | |
KR20190045242A (en) | Spirocyclic Inhibitors of Menin-MLL Interactions | |
CA2534496A1 (en) | Pyrimidylpyrrole derivatives active as kinase inhibitors | |
ES2308260T3 (en) | DERIVATIVES OF IMIDAZOPIRIDINS AS INHIBITORS OF INDUCIBLE NON-SYNTHEASE. | |
US20220098208A1 (en) | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives | |
RU2809779C2 (en) | Pyrazolotriazine and/or pyrazolopyrimidine derivatives as a selective cyclin-dependent kinase inhibitor | |
CA3183321A1 (en) | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases | |
ES2611170T3 (en) | New derivatives of pyrimidine as phosphodiesterase 10 (PDE-10) inhibitors | |
WO2022248682A1 (en) | Compounds for degradation of cyclin-dependent kinase 7 (cdk7) | |
WO2022117504A1 (en) | Compounds having cyclin-dependent kinase(cdk)-inhibitory function | |
KR20220041124A (en) | Thienopyridinyl and Thiazolopyridinyl Compounds Useful as IRAK4 Inhibitors | |
KR20220136395A (en) | Tricyclic Heteroaryl Compounds Useful as IRAK4 Inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19720425 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3095880 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2019250507 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2020555100 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020020768 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2019250507 Country of ref document: AU Date of ref document: 20190411 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20207032379 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019720425 Country of ref document: EP Effective date: 20201111 |
|
ENP | Entry into the national phase |
Ref document number: 112020020768 Country of ref document: BR Kind code of ref document: A2 Effective date: 20201009 |